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ROLE OF EXERCISE AND GDNF IN AN ANIMAL MODEL OF 
PARKINSON’S DISEASE: IMPLICATIONS FOR NEUROPROTECTION 
 
Ann D. Cohen 
University of Pittsburgh, 2006 
 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder resulting in part 
from loss of nigrostriatal dopamine (DA) neurons. Treatments act only to relieve symptoms. It is 
therefore essential to develop treatments that slow or reverse the neurodegenerative process. 
Here, I explored exercise as a potential treatment against a 6-hydroxydopamine (6-OHDA) rat 
model.  
 6-OHDA causes selective loss of DA neurons, a PD model. Forced limb use after 6-
OHDA ameliorates behavioral and striatal DA effects. Further, exercise increases trophic factors, 
such as GDNF, that have neuroprotective qualities in this model. I explored the effects of forced 
limb use prior to 6-OHDA on the effects of the toxin and GDNF levels in the striatum. I 
demonstrated that prior forced limb use attenuated the behavioral deficits and loss of DA typical 
of 6-OHDA and increased GDNF in the striatum of animals exposed to forced use.  
 The protective effect of exercise could reflect a decrease in the vulnerability of DA 
neurons, a regeneration of axons, or sprouting of axon terminals from undamaged neurons. Thus, 
I investigated the hypothesis that casting induced neuroprotection was due to the preservation of 
DA cells and terminals. Here, I demonstrated that forced limb use protected from 6-OHDA 
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induced loss of DA neurons and terminals. These findings suggest that exercise exerts its effects 
by decreasing the vulnerability of DA neurons and terminals to 6-OHDA.  
Because casting increased GDNF, I next examined the effects of GDNF on 6-OHDA 
neurotoxicity during the 8 wk period after 6-OHDA. Using phenotypic markers of the 
nigrostriatal system, a non-DA cellular marker, and striatal DA content, I demonstrated these 
markers in the striatum and SN were not protected at 2 wks after 6-OHDA  but recovered by 8 
wks. No loss of DA cells in the SN or DA content in the striatum was observed in animals 
pretreated with GDNF. These data suggest that GDNF prevents 6-OHDA-induced DA cell 
death, but that weeks are required before these cells begin to normally express phenotypic 
markers. In conclusion, exercise may function to enhance the brain’s ability to produce trophic 
factors, which may slow or halt the degenerative process in PD.  
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1.0 Introduction 
 
1.1 Parkinson’s Disease is a progressive neurodegenerative disorder. 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting 1% of 
individuals above age 55. The pathology of PD was first characterized by a loss of dopamine 
(DA)-containing neurons projecting from the substantia nigra (SN) to the dorsal striatum 
(Hornykeiwicz, 1966) but it has been suggested that many other factors play a role in the 
symptoms and etiology of the disease. For example, damage to glutamatergic, GABAergic 
noradrenergic, cholinergic, and serotonergic neurons have all been reported in PD (Riederer and 
Lang, 1992; Braak et al., 1996; Hirsch, 2000; Braak et al., 2003). Indeed, some have suggested 
that several of these changes occur during the preclinical phase of PD before symptoms or loss 
of DA occur (Braak et al., 1996; 2003; Przuntek et al., 2004).  
Despite the evidence of widespread pathology associated with PD, there is strong 
evidence to indicate that the loss of DA plays a crucial role in PD. The loss of DA in the 
putamen and DA cells in the SN is highly correlated with the motor symptoms associated with 
PD (see: Hornykeiwicz, 1966). Additionally, the primary treatment for the symptoms of PD is 
replacing DA levels through levodopa (L-DOPA) treatment, which is also consistent with the 
assumption that the loss of DA is a primary cause of the motor symptoms of PD.  Further 
evidence for the critical role of DA in PD exists from animal models such as 6-hyroxydopamine 
(6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyradine (MPTP), and rotenone, which have 
been shown to selectively destroy DA neurons while producing hallmark symptoms of PD.  
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 1.1.1 PD produces motor deficits and non-motor symptoms 
PD produces hallmark clinical features including tremor; rigidity; bradykinesia, a 
slowness of movement; akinesia, an inability to move; and postural and gait abnormalities. 
Although PD is primarily associated with motor symptoms, several non-motor features 
commonly present in this disorder. Depression, masked face, cognitive deficits, and anosmia are 
all commonly reported in patients with PD.  
 1.1.2 PD produces a distinct neuropathology 
Late stages of PD produce losses of numerous cell types but typically the disease has 
been characterized by the loss of DA neurons. Postmortem examination of PD brains reveals a 
loss of DA neurons in the SN and a loss of DA terminals in the caudate and putamen of the 
dorsal striatum (for review see: Bernheimer et al., 1973). In addition to loss of nigrostriatal DA 
neurons and terminals, later stages of PD produce decreases in DA cell number in the ventral 
tegmental area and DA terminals in the nucleus accumbens and cortex. Additionally, loss of 
both norepinephrine and serotonin containing neurons has been reported in PD. It has been 
suggested these non-nigrostriatal losses are primarily associated with the non-motor deficits of 
the disease discussed above.  
1.1.3 The causes of PD are unknown 
Little is known about the causes of PD, although a leading hypothesis is that PD results 
from the selective loss by apoptosis of DA neurons due to oxidative stress through the 
production of reactive oxygen species (ROS). In addition to oxidative stress, others have 
suggested dysfunction in mitochondrial respiration, proteasomal inhibition, as well as roles for 
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genetic mutations and environmental toxins (For reviews: Dawson & Dawson, 2003; Landrigan 
et al., 2005; Abou-Sleiman et al., 2006; Farrer, 2006). I have chose here to focus on oxidative 
stress and have selected an animal model that utilizes ROS as a primary means for producing 
DA cell death (see below).  
1.1.4 The role of oxidative stress in PD  
A leading hypothesis is that PD results from the selective loss by apoptosis of DA 
neurons due to oxidative stress through the production of ROS. ROS are highly reactive causing 
damage to cells through damage of proteins and DNA, impairing a cells ability to function 
(Cohen and d’Arcy Doherty, 1987). The brain is uniquely susceptible to ROS for several 
reasons including its high iron content and oxygen utilization and the presence of highly 
reactive neurotransmitters (for review see: Bharath et al., 2002). This seems to be particularly 
true in the DA system, where the highly reactive nature of DA has been suggested to produce 
damaging levels of ROS on its own and to enhance damage produced by other neurotoxins (for 
review see: Hastings and Zigmond, 1997). Indeed, increased indices of oxidative stress (Olanow 
and Tatton, 1999) and decreased levels of glutathione (GSH), an antioxidant, (Perry and Yong, 
1986; Jenner, 1993) have been observed in postmortem brains from PD patients. Additionally, 
the catecholaminergic neurotoxin 6-OHDA, which is used to generate an animal model of PD, 
does so through oxidative stress (Sachs and Jonsson, 1975; Heikkila and Cohen, 1972; Zigmond 
and Keefe, 1997) and this toxicity can be enhanced by removing endogenous antioxidant 
defenses (Pileblad et al., 1989; Garcia et al., 2000).  
1.1.5 Role for genetics in the pathogenesis of PD 
Although no single gene is thought to cause PD, several genetic mutations have been 
found to play a role in the pathogenesis of the disease. Several genes including those encoding 
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alpha-synuclein, PINK-1, Parkin, and DJ-1 are associated with familial linked early onset PD, 
which is often accompanied by dementia (Polymeropoulos et al., 1997; Kitada et al., 1998; 
Bonifati et al., 2003; Valente et al., 2004; Abou-Sleiman et al., 2005). Later onset PD has been 
associated with several genetic mutations, including genes for the leucine-rich repeat kinase 2 
(LRKK2) and ubiqutin carboxyl-terminal esterase L-1 (UCHL1). These genes vary in their 
function including disruption of intracellular signaling, impairment of cellular respiration, and 
impairment of cytoskeletal transport (for review see: Farrer, 2006). One prevailing hypothesis is 
that in idiopathic PD, these genetic disruptions paired with environmental stressors (see below) 
could combine to produce the pathology of the disease.  
1.1.6 Role for environment in the pathogenesis of PD 
 The most well known environmental cause of PD can be attributed to MPTP, a synthetic 
chemical known to inhibit mitochondrial respiration, now utilized widely as an animal model of 
PD. MPTP was first described after use among a group of drug users in California who 
developed the cardinal symptoms of PD (Langston et al., 1983). In addition to MPTP, several 
pesticides have been implicated in the pathogenesis of PD. In fact, organochlorides have been 
found to be elevated in PD brains (Fleming et al., 1994). The insecticide rotenone, also a 
complex 1 inhibitor, is one of the most well known environmental toxins associated with PD, as 
it has recently become widely used in an animal model of PD (Betarbet et al., 2000). The 
herbicide paraquat and the fungicide maneb have both been associated in epidemiological studies 
with PD (eg. Brooks et al., 1999;  McCormack et al., 2002) and have been shown to produce DA 
cell death in animal models (Thiruchelvam et al. 2000a; 2000b; Liu et al. 2003). In addition to 
pesticides, PD has been associated with environmental exposure to heavy metals, well water, and 
other agricultural chemicals (see Landrigan et al., 2005). It is likely that exposure to any of these 
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factors may pair with a genetic predisposition to develop PD.  
 
1.2 There are various approaches that might be taken to slow or even reverse 
DA neuron degeneration.  
Most current forms of treatment are designed to provide a supplemental source of 
stimulation for DA receptors. Often these treatments seek to stimulate DA receptors, either 
directly or indirectly. L-DOPA is the most common such example. Other approaches involve 
neurosurgical techniques. However, none of the currently available treatments are able to 
completely eliminate the symptoms and none have been clearly shown to halt the progression of 
this disease. Thus, exploration of alternative approaches is warranted. Several longer-term 
approaches have been proposed. These include (a) transplantation of cells that can synthesize 
and release DA or its precursor, (b) administration of a trophic factor such as GDNF (see 
below), (c) introduction of a gene that would increase the synthesis of either DA or a 
neuroprotective factor, or (d) the administration of a drug (e.g., deprenyl or pramipexol) that has 
been shown in one or another model system to have neuroprotective effects.  
 
1.3 6-OHDA rat model of PD 
1.3.1 6-OHDA-induced toxicity is a useful animal model of PD.  
Animal models of PD have been produced using the catecholaminergic neurotoxin 6-
OHDA (Ungerstedt, 1971; Zigmond and Keefe, 1997). When delivered intracerebrally to rats in 
conjunction with a norepinephrine (NE) uptake inhibitor, 6-OHDA causes selective loss of DA 
neurons via oxidative stress, a proposed mechanism in the pathogenesis of PD (Halliwell, 
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2001). As 6-OHDA is a structural analog of catecholamines, it is able to enter DA neurons via 
the DA transporter (DAT) and is rapidly oxidized into 6-OHDA-quinone and hydrogen 
peroxide (Fig 1.1) (for review, see Zigmond and Keefe, 1997). 
 
Figure 1.1: 6-OHDA is rapidly oxidized to the toxic byproducts 6-OHDA 
quinone, hydrogen peroxide (H2O2), superoxide radical (O2-), and hydroxyl radical 
(OH˙). (Modified from Zigmond and Keefe, 1997). 
HO
HO
OH
NH2
O
HO O
NH2
O2 H2O2, OS-, OH˙
6-HYDROXYDOPAMINE 6-HYDROXYDOPAMINE P-QUINONE
As will be discussed below, the location of the infusion of 6-OHDA along the 
nigrostriatal bundle also plays a role in the magnitude and duration of DA neuronal degeneration.   
1.3.2 Medial Forebrain Bundle Lesion 
6-OHDA placed along the medial forebrain bundle (MFB) produces a rapid degeneration 
of DA neurons and terminals where a loss of DA levels in the striatum can be detected by 24 
hours after 6-OHDA and a significant loss of DA neurons in the SN by 3 days post-6-OHDA 
(Willis et al., 1976; Perese et al., 1989; Smith et al., 2003). In addition to producing a large, 
reliable cell death to the nigrostriatal pathway, unilateral MFB infusions produce reliable, long-
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lasting behavioral deficits that can be easily measured after 6-OHDA infusion (Schallert et al., 
2000). A major issue regarding placement of 6-OHDA along the MFB is that of specificity. 
Because 6-OHDA is a catecholamine analog and not simply an analog of DA, when placed in 
the MFB 6-OHDA can produce damage to NE terminals. In order to create specific damage to 
only DA neurons, 6-OHDA can be used in conjunction with a NE uptake inhibitor, thereby 
blocking entry of 6-OHDA into NE terminals. Indeed, use of desipramine, an NE uptake 
inhibitor, has been shown to prevent loss of NE terminals but not DA terminals after 6-OHDA 
infusion (Breese and Traylor, 1971; Hernandez and Hoebel, 1982). One drawback to the MFB 
lesion is that it can produce (depending on dose) a rather large and rapid cell death that can 
sometimes overwhelm potential neuroprotective strategies that may take longer time periods to 
produce beneficial effects. Additionally, because of the speed with which MFB lesions produce 
death of DA neurons, it does not closely mimic the clinical condition.   
1.3.3 Striatal Lesion 
6-OHDA delivered into the striatal DA terminals is another option for the destruction of 
the nigrostriatal pathway that has been widely used to examine neuroprotective strategies. 
Delivery of 6-OHDA into the striatum produces a slower, more progressive degeneration of DA 
neurons as death and retraction of the striatal terminals is required for subsequent neuronal 
death in the SN (Sauer and Oertel, 1994). One major advantage of this model is that it damages 
only a subset of DA neurons, allowing for examination of neuroprotective strategies. Because 
the cell death in the SN is protracted the striatal lesion model allows for an examination of 
neuroprotective strategies applied after the cell death process has already begun, which in the 
long term may be clinically relevant. Additionally, because in the striatum there are no NE 
terminals, this allows 6-OHDA to be specific to DA without drug pre-treatment. One drawback 
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to a striatal model is that behavioral deficits can be more difficult to detect because only a 
subset of DA neurons are affected, thus behavioral deficits are more subtle. Additionally, 
because loss of neurons in the SN is only partial it can be difficult to detect decreases in the 
number of neurons without use of a retrograde tracer, such as Fluoro-gold (eg Sauer and Oertel, 
1994). 
1.3.4 DA depletions produce motor neglect 
One feature of PD is that movement is difficult and inactivity becomes more prominent 
as the disease progresses. Early in the disease, as the first fraction of the dopaminergic cells are 
in the process of degeneration, patients may learn to engage in alternative behavioral strategies 
that lead to even greater dependence on less compromised motor systems, an observation 
typical of animal models of the disease (Schallert & Hall, 1988; Schallert, 1988; Lees, 1992; 
Schallert et al., 2000a; Whishaw, 2000). Additionally, like patients with PD, 6-OHDA-infused 
rats can show paradoxical kinesia. For example, they show transient improvements in motor 
performance when placed in an ice bath or exposed to a cat (Marshall, 1979), returned to their 
home cage after exposure to an unfamiliar environment (Schallert, 1989), or placed in a deep 
pool of water (Marshall, 1979; Keefe et al., 1989; 1990). Thus, it is possible that a program of 
motor therapy that targeted motor processes normally affected by 6-OHDA might retard the 
neurodegenerative cascade. 
 
1.4 Exercise is neuroprotective 
1.4.1 Exercise is neuroprotective after brain damage 
Constraining the non-impaired upper extremity in stroke patients, thereby forcing use of 
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the affected limb, has been shown to improve motor function after stroke (Taub et al., 1999). 
Additionally, constraint induced therapy appears to induce reorganization in brain regions 
affected by ischemic brain damage (Taub and Morris, 2001; Sterr et al., 2002). Constraint 
therapy has also been used to improve functional outcome and expand neurophysiologically 
mapped limb representation areas in primate models and in humans after motor cortex injury 
(e.g., Liebert et al., 2000). Exercise and enriched environments have been shown to protect in 
several models of brain damage and have been shown to be neuroprotective in animals 
subjected to a variety of neurotoxic conditions, including ischemia, (Stummer et al., 1994, Li et 
al., 2004), 3-acetylpyrine, domoic acid, (Carro et al. 2001), and genetic modifications associated 
with Alzheimer’s disease (Allard et al., 2005; Jankowsky et al., 2005; Sisodia et al., 2005). 
1.4.2 Exercise is beneficial in PD and animal models of PD 
Increases in physical activity levels throughout life have been associated with a lower 
propensity to develop PD (Sasco et al., 1992; Tsai et al., 2002; Hirsch et al., 2003; Chen et al., 
2005). There is also evidence for efficacy of physical therapy regimens in the treatment of PD 
(Toole et al., 1999, Bergen et al., 2002). A similar effect of exercise has been observed in 
animal models of PD. For example, treadmill and exercise in a running wheel, as well as an 
enriched environment, has been shown to reduce the effects of another DA-selective neurotoxin, 
MPTP in a mouse model (Bezard et al., 2003; Tillerson et al., 2003; Faherty et al., 2005). We 
and our colleagues have shown that placing a cast on one forelimb for 7 days immediately 
following the unilateral administration of 6-OHDA can attenuate both the behavioral and 
neurobiological effects of the toxin (Tillerson et al., 2001; 2002; Fig 1.2). 
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1.4.3 Exercise induces neuroprotective responses in the brain 
Motor training and enriched experience have been associated with glial cell proliferation, 
changes in neurotransmitter levels (Bland et al., 1999; Humm et al., 1999), and the growth of 
neuronal processes (e.g., Jones & Schallert, 1994; Kleim et al., 1996; Schallert et al., 1997; 
Kempermann et al., 1998a; for reviews see: Kolb & Whishaw, 1998; Klintsova & Greenough, 
1999, Ivanco & Greenough, 2000). Additionally, exercise produces a robust effect on trophic 
factor expression, including GDNF, BDNF, and FGF2. The mRNA for BDNF can be 
upregulated in the hippocampus and cerebral cortex in response to physical exercise (Neeper et 
al., 1995, 1996; Oliff et al., 1998; Russo-Neustadt et al., 1999; Widenfalk et al., 1999; Russo-
 
 
Fig 1.2: Effect of forced use on DA, DOPAC, and HVA levels. Shown are means ± 
SEM of sham (open bars, n=13), 6-OHDA lesioned (hatched bars; 12), and lesioned/casted 
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Neustadt et al., 2001). Additionally, exercise deprivation after a prolonged period of habitual 
running down-regulates hippocampal BDNF and TrkB (Widenfalk et al., 1999). NGF, another 
neurotrophin, is also increased in the hippocampus and cerebral cortex in response to physical 
exercise (Neeper et al., 1996). FGF2 is also increased during exercise (Gomez-Pinilla et al., 
1997). Moreover, it has been observed that FGF2 is increased in astrocytes in the perinjury area 
of cortex in both the MCAo and focal ablation injury models, and that forced non-use of the 
impaired forelimb reduces both endogenous expression of FGF2 and the extent of dendritic 
arborization in layer V pyramidal neurons in the region surrounding the infarct (Schallert et al., 
2000). Although not examined to the extent of BDNF, there is emerging evidence that GDNF 
may also play a role in the effects of exercise. For example, GDNF is upregulated in the 
hippocampus of rats raised in an enriched environment (Young et al., 1999).   
Exercise may function to increase trophic factors in several ways. First, exercise could 
induce motor learning processes, which have been shown to increase trophic factors (Gomez-
Pinilla et al., 1998). Second, exercise has been shown to increase glial cell proliferation and glia 
have been hypothesized to function to release endogenous trophic factors. Finally, another 
possibility is that exercise produces a drop in body weight, which has also been shown to 
increase endogenous levels of trophic factors (Lee et al., 2000).  
  
1.5 Neuroprotective factors may be a useful treatment for PD. 
GDNF is a dimeric protein expressed in several cell populations and has been shown to 
be highly expressed in the developing rat striatum (Stromberg et al., 1993) making it an 
interesting factor to be exploited against degeneration of the nigrostriatal DA system. GDNF is 
a survival factor for DA neurons (Fig 1.3) that can protect against toxic insults in adult animals. 
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Early studies of DA neurons in culture indicated the presence of a survival factor (e.g., Engele 
and Bohn 1991), which was soon identified as GDNF (Lin et al., 1993). In the presence of this 
factor, DA neurons increase in size and have longer processes forming a denser network of 
dendrites and axons than DA cells lacking GDNF exposure (Lopez-Martin, 1999). GDNF is a 
member of the transforming growth factor β (TGF-β) superfamily. In mouse and rat brains, 
GDNF expression rapidly falls off as development proceeds (Stromberg et al., 1993; Blum & 
Weickert, 1995). However, there are many instances in which aspects of recovery of function 
recapitulate ontogeny (see review by Cramer & Chopp, 2000), and there is evidence that GDNF 
expression can increase following injury (Naveilhan et al., 1997; Liberatore et al., 1997; 
Sakurai, et al., 1999; Wei et al., 2000).  
+ GDNF 
 
 
 
 
 
 
 
 
 
Fig 1.3: The effects of GDNF on primary cultured TH+ neurons (Adapted from Ding 
et. al., 2003)  
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Increased GDNF expression, whether through the addition of exogenous GDNF or 
following the administration of a viral vector containing the GDNF gene, can protect DA 
neurons against the neurotoxic effects of 6-OHDA. This has been shown both in vivo and in 
vitro (e.g., Hoffer et al., 1994; Kearns & Gash, 1995; Choi-Lundberg et al., 1997; Akerud et al., 
1999; Kramer et al, 1999; Gong et al., 1999; Schatz et al., 1999; Zigmond et al., 2000; Smith et 
al., 2003). The neuroprotective effects of GDNF extend to other insults and other cell types (e.g., 
McAlhany et al., 2000). Furthermore, decreased levels of GDNF are observed in patients with 
PD, which suggest loss of trophic support is a causal factor in the genesis of the disease (Siegel 
and Chauhan 2000). While animal studies have been quite promising, clinical data on the effects 
of GDNF on the progression of Parkinson’s disease remains limited as some groups have shown 
improvements in symptoms and progression of PD (Gill et al., 2003; Patel et al., 2005; Slevin et 
al., 2006) while others have shown no clinical improvement (Nutt et al., 2003; Lang et al., 2006). 
 
1.6 The dissertation 
Treatments for PD are generally limited and these treatments do not appear to reduce the 
progression of the disease. Moreover, side effects of these treatments gradually emerge and 
efficacy usually is reduced. Thus, developing strategies for slowing or preventing ongoing 
degeneration or even reversing the neurodegenerative process in PD is of paramount importance 
I therefore set out in the broad aims of the dissertation to provide evidence for the following 
hypotheses:  
Exercise prior to oxidative stress directed toward DA neurons in the SN reduces the 
vulnerability of DA neurons to oxidative stress. The underlying mechanism of these 
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protective effects involves an increase in trophic factors, which protect DA neurons 
against such stress. 
To test these hypotheses I have used as my model adult male rats exposed to 6-OHDA. 
The exercise that I have chosen is 7 days of forced limb use caused by casting the contralateral 
limb. Moreover, the trophic factor on which I have focused is GDNF. 
Our research group, working together with Dr. Tim Schallert and his associates at the 
University of Texas, Austin, had previously shown that forced reliance on the impaired forelimb 
is protective if performed for the 7 days immediately following 6-OHDA (Tillerson et. al., 2001; 
2002). Chapter 2 examines the effect of forced reliance on a forelimb during the 7 days prior to 
ipsilateral infusion of 6-OHDA on the deficits characteristic of this lesion model. I additionally 
tested the hypothesis that forced-use might increase the expression of endogenous GDNF thereby 
attenuate the effects of 6-OHDA. Casted animals displayed no behavioral asymmetries and a 
marked attenuation in the loss of striatal DA and its metabolites. Animals receiving a unilateral 
cast alone showed an increase in GDNF protein in the striatum corresponding to the overused 
limb. These results suggest that pre-injury forced limb-use can prevent the behavioral and 
neurochemical deficits to the subsequent administration of 6-OHDA and that this may be due in 
part to neuroprotective effects of GDNF. 
Chapter 2 demonstrates that prior forced limb use confers protection from the behavioral 
and neurochemical effects of 6-OHDA. However, it is not known whether this reflects (a) a 
decrease in the vulnerability of DA neurons to 6-OHDA, (b) a regeneration of damaged DA 
axons, or (c) the sprouting of DA axon terminals from undamaged neurons into areas initially 
affected by 6-OHDA. Chapter 3 investigated the hypothesis that the ability of casting to block 
the behavioral and neurochemical effects of 6-OHDA is due in part to the preservation of DA 
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cells and terminals, by using tyrosine hydroxylase (TH) to measure the loss of nigrostriatal 
terminals and neurons and Nissl to measure the presence of SN neurons. Animals casted prior to 
6-OHDA showed a significant attenuation of normal loss of both TH immunoreactive and Nissl-
stained cells in the SN. Precasted animals also showed a significant sparing of TH+ terminals in 
the striatum. These data suggest that prior forced limb use produces behavioral and 
neurochemical protection by decreasing the vulnerability of DA neurons to oxidative stress.   
The mechanism underlying the protective effect of forced limb use is unknown. 
However, in Chapter 2  I showed that glial cell-line derived neurotrophic factor (GDNF), a 
potent dopaminotrophic factor that protects against 6-OHDA toxicity (e.g., Kearns and Gash, 
1995; Choi-Lundberg et al, 1998), was increased in the striatum with forced limb use, indicating 
that it may be involved in the protective effects of forced limb use against 6-OHDA.  
In Chapter 4, I explored the effects of GDNF on 6-OHDA neurotoxicity during the 8 wk 
period following administration of the toxin, using several phenotypic markers of the 
nigrostriatal system, a non-DA cellular marker, and DA content in the striatum. At 2 wks post-
infusion, TH, the vesicular monamine transporter 2 (VMAT2), and the dopamine transporter 
(DAT) displayed a loss in the striatum of GDNF-treated animals that was similar to the loss of 
these markers in 6-OHDA treated animals that did not receive GDNF. As expected, at 8 wks 
post-infusion, GDNF pre-treated animals had only a 20-30% loss depending upon the 
dopaminergic marker assessed. Similarly, when FG-positive cells were examined in the SN of 
GDNF pre-treated animals, no loss of cells was observed at 8 wks. Analysis of FG cells in SN 
and of DA levels in striatum indicated that GDNF-protection was complete by 2 wks. However, 
a marked loss of TH cells and of TH, VMAT2, and DAT in striatum was observed at that earlier 
time point. Additionally, no loss of DA content was observed in the striata of GDNF pre-treated 
 15 
animals. Taken together, these data suggest that GDNF prevents 6-OHDA-induced DA cell 
death, but that weeks are required before these cells to begin to normally express many 
phenotypic markers. 
In summary, the data presented in this dissertation suggest that exercise and GDNF are 
viable treatment options for Parkinson’s disease. Further exploration of the neuroprotective 
effects of GDNF or exercise on a 6-OHDA model will provide insight into design and 
methodology of future clinical studies for treatment options in PD. Finally, as the mechanisms of 
the protective effects of GDNF and exercise are further explored more targets for drug creation 
may become available, particularly as early detection methods become more readily available.  
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 2.0 Neuroprotective effects of prior limb use in 
6-hydroxydopamine-treated rats:  Possible role of GDNF 
 
2.1 Abstract  
Unilateral administration of 6-OHDA into the MFB causes a loss of DA in the ipsilateral 
striatum and contralateral motor deficits. However, if a cast is placed on the ipsilateral limb 
during the first 7 days following 6-OHDA infusion, forcing the animal to use its contralateral 
limb, both the behavioral and neurochemical deficits are reduced. Here, we examine the effect of 
forced reliance on a forelimb during the 7 days prior to ipsilateral infusion of 6-OHDA on the 
deficits characteristic of this lesion model. Casted animals displayed no behavioral asymmetries 
as measured 14-28 days post-infusion and a marked attenuation in the loss of striatal DA and its 
metabolites at 30 days. In addition, animals receiving a unilateral cast alone had an increase in 
GDNF protein in the striatum corresponding to the overused limb. GDNF increased within 1 day 
after the onset of casting, peaked at 3 days, and returned to baseline within 7 days. These results 
suggest that pre-injury forced limb-use can prevent the behavioral and neurochemical deficits to 
the subsequent administration of 6-OHDA and that this may be due in part to neuroprotective 
effects of GDNF. 
2.2 Introduction  
PD is a neurological disorder characterized by the degeneration of DA cells in the 
substantia nigra. The loss of dopaminergic control over striatal output neurons leads to a variety 
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of neurological deficits, including akinesia. Most current treatments for PD are pharmacological, 
temporarily restoring dopaminergic tone in the striatum, and therefore focus on alleviating 
symptoms of the disorder. However, when the degree of DA cell loss becomes too extensive, the 
efficacy of drug treatment diminishes, and motor and psychiatric side effects become more 
problematic. Thus, it is essential to develop strategies for slowing or preventing ongoing cell 
death in this disorder.  
Animal models of PD have been produced using the catecholaminergic neurotoxin 6-
OHDA (Ungerstedt, 1971; Zigmond and Keefe, 1997). When delivered intracerebrally to rats, 6-
OHDA causes selective loss of DA neurons via oxidative stress, a proposed mechanism in the 
pathogenesis of PD (Halliwell, 2001), and a marked impairment in limb use for movement 
initiation or skilled motor functions (e.g., Marshall et al., 1974; Spirduso et al., 1985; Schallert et 
al., 1992; Miklyaeva and Whishaw, 1996). However, like patients with PD, 6-OHDA-infused 
rats can show paradoxical kinesia. For example, they show transient improvements in motor 
performance when placed in an ice bath or exposed to a cat (Marshall et al., 1976), returned to 
their home cage after exposure to an unfamiliar environment (Schallert, 1989), or placed in a 
deep pool of water (Marshall et al., 1976; Keefe et al., 1989; 1990).  
Increases in physical activity levels throughout life have been associated with a lower 
propensity to develop PD (Sasco et al., 1992; Tsai et al., 2002). Additionally, constraining the 
non-impaired upper extremity in stroke patients, thereby forcing use of the affected limb, 
improves the motor function and increases the use of the affected limb (Taub et al., 1999; Taub 
and Morris, 2001; Sterr et al., 2002). There is also limited evidence for efficacy of physical 
therapy regimens in the treatment of PD (Toole et al, 1999).  
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We have recently shown that forcing animals to exercise their impaired limb for 7 days 
beginning 0-3 days after the unilateral administration of 6-OHDA can dramatically attenuate 
both the behavioral and neurobiological effects of the toxin (Tillerson et al., 2001; 2002). 
Although the mechanism by which forced use ameliorates behavioral and biochemical deficits is 
unknown, one hypothesis that can be drawn from the literature is that forced use of the impaired 
forelimb initiates a cascade of events that involves an increase in the availability of key 
neurotrophic factors in the brain. One such factor is GDNF. 
GDNF has been shown to be a potent survival factor for DA neurons (Lin et al., 1993). 
Moreover, administration of exogenous GDNF or a viral vector containing the GDNF gene is 
known to protect DA neurons from the neurotoxic effects of 6-OHDA in vitro (Kramer et al, 
1999; Gong et al., 1999; Schatz et al., 1999) and the behavioral and neurotoxic effects in vivo 
(Hoffer et al., 1994; Kearns & Gash, 1995; Choi-Lundberg et al., 1998; Akerud et al., 1999). 
Although levels of GDNF protein decrease markedly after development, there is evidence that 
GDNF can increase after experience, such as an enriched environment (Young et al, 1999). We, 
therefore, reasoned that forced-use might increase the expression of endogenous GDNF and 
attenuate the effects of 6-OHDA.  
 
2.3 Materials and Methods 
Animals 
Male rats weighing 350-450 grams were used throughout these experiments. All animals 
were housed two per cage and maintained on 12 h light/dark cycle with food and water available 
ad libitum. All procedures were in strict accordance with the guidelines for the NIH Care and 
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Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committees at the University of Texas and the University of Pittsburgh. The studies reported 
here of the effects of casting on the behavioral and neurochemical effects of 6-OHDA were 
carried out in hooded Long-Evans rats (Charles River Laboratories, Wilmington, MA), whereas 
studies of GDNF were carried out with Sprague-Dawley rats (Hilltop Lab Animals, Scottsdale, 
PA). A small pilot study indicated that the neuroprotective effects of casting seen with the Long-
Evans strain (see Figures 2.1-2.3) were comparable to those seen with Sprague-Dawley strain 
(see legend to Figure 2.4). In addition, previous investigators also have found that forced 
exercise has the same effect on 6-OHDA infused rats from the Long-Evans and Sprague-Dawley 
strains (Moroz et el., 2002; Tillerson et al., 2002). 
 
Preoperative and Surgical Procedures 
Seven days prior to surgery animals were randomly assigned to one of four groups. 
Sham-lesioned/casted animals (n=3) received a cast for the 7 days prior to the sham lesion; 
sham-lesioned animals (n=2) received a sham lesion alone; 6-OHDA animals (n=9) received 
unilateral 6-OHDA alone, whereas casted/6-OHDA animals (n=7) received a cast on one limb 
for 7 days prior to being given an ipsilateral infusion of 6-OHDA into the MFB.  
Animals in the casted groups were fitted with plaster of Paris casts to immobilize the 
forelimb in a naturally retracted position against the sternum (Jones and Schallert, 1994). At the 
end of the 7-day casting period, all animals were anesthetized with Equithesin (25 mg/kg 
pentobarbital and 150 mg/kg chloral hydrate, i.p.), the casts were removed (if present), and the 
animals were prepared for surgery. Animals began to use the previously casted forelimb 
immediately upon awakening from surgery. Thirty minutes prior to surgery, animals were given 
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desipramine (15 mg/kg, i.p.), an inhibitor of norepinephrine uptake that serves to block the entry 
of 6-OHDA into noradrenergic neurons. 6-OHDA (10 µg in 4 µl of 0.9% NaCl, 0.02% ascorbic 
acid) was infused (0.5 µl/min) into either the right or left MFB  (the side ipsilateral to the cast; 
3.3 mm posterior, ± 1.7 mm lateral of bregma, and 9 mm ventral to dura) (Paxinos and Watson, 
1982). Sham-lesioned animals received all surgical procedures up to but not including lowering 
of infusion cannulae.  
 
Behavioral Assessment 
One week before and 2-4 wks after infusion, animals were assessed for forelimb 
asymmetry and akinesia. The extent of asymmetry in the forelimbs during exploratory 
movements was determined by videotaping rats in a clear Plexiglass cylinder (20 cm diameter; 
30 cm high) for 3 min and later analyzing a slow motion version of the tape (Schallert & 
Tillerson, 2000; Tillerson et al., 2001, 2002; Cenci et al., 2002; Schallert, 2002). We assessed the 
amount of time animals made independent use of the impaired forelimb, the independent use of 
the non-impaired forelimb, and the simultaneous use of both limbs (including alternating steps) 
for support and weight shifting movements along the walls. For a single score, these values were 
converted to percentages and the percent independent use of the non-impaired forelimb was 
subtracted from the percent independent use of the impaired forelimb. To assess forelimb 
akinesia, animals were held with their hindquarters suspended and allowed to initiate stepping 
movements in a 10-sec period. Stepping movements were assessed for both limbs and an 
asymmetry score was computed [(ipsilateral steps/ipsilateral plus contralateral steps) – 
(contralateral steps/ipsilateral plus contralateral steps)] (Schallert and Tillerson, 2000; Schallert 
et al., 1992; Cenci et al., 2002). Three weeks post-infusion animals received apomorphine (0.5 
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mg/kg, s.c.), were placed in a 14.5 in. diameter plastic bowl and rotations were counted over a 
90-min period to estimate the extent of denervation induced upregulation of DA receptors 
(Ungerstedt, 1971). 
 
Neurochemical Assessment 
Dopamine assay: Thirty days post-infusion, animals from sham-lesioned, sham-
lesioned/casted, 6-OHDA, and casted/6-OHDA groups were sacrificed, brains were removed, 
and a section of the striatum from 1 to 2 mm anterior of bregma was dissected from both the 
ipsilateral and contralateral hemispheres. Dissected striata were assayed using minor 
modifications of previous methods (Smith et al., 2002). Striatal tissue was suspended in 0.1 M 
HClO2 containing 347 μM NaHSO3 and 134 μM Na2 EDTA in a volume (µl) 20X weight in mg, 
homogenized and centrifuged at 16,000 x g for 20 min at 4°C, and the supernatant was removed. 
Tissue samples were assayed for DA and 3,4-dihydroxyphenylacetic acid (DOPAC) by injecting 
a 10 μl aliquot of the sample onto a Symmetry C18 column (3.9 x 140 mm, Waters Corporation, 
Milford, MA). The mobile phase consisted of 50 mM H2NaPO4, 0.72 mM sodium octyl sulfate, 
0.075 mM Na2EDTA and 16% methanol (v/v), pH 2.7. The mobile phase was pumped through 
the system at 0.7 ml/min using a Shimadzu LC-10AD pump (Shimadzu Corp., Columbia, MD). 
Analyses were detected coulometrically using an ESA Coulochem Model 4100A detector, an 
ESA Model 5010 conditioning cell, and an ESA Model 5014B microdialysis cell (ESA, Inc., 
Chelmsford, MA). The settings for detection were E1=+0.26V, E2=+0.28V, and guard cell=+0.4 
V. The limits of detection for DA and DOPAC were in the femtomole range. 
GDNF assay: Thirty-three male Sprague Dawley rats were casted and decapitated 1-10 
days after placement of the cast, and the striata were removed, homogenized in lysis buffer 
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containing 137 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1% NP40, 10% glycerol, 1 mM 
phenylmethylsulphonyl fluoride (10 μg/ml), and 0.5 mM sodium vanadate. Homogenate was 
then centrifuged at 12,000 x g for 20 min at 4°C, supernatant was removed, acid-treated with 1 N 
HCl (1 µl/10 µl of sample), and then neutralized with 1 N NaOH (1 µl/10 µl of sample), 
respectively, to increase the sensitivity of the assay (Okragly and Haak-Frendscho, 1997). 
Samples were assayed for GDNF using an ELISA kit (Promega Corporation, Madison, WI) 
according to the protocol provided. GDNF values were compared to those observed in uncasted 
animals. 
 
Statistical Analysis 
Neurochemical, trophic factor, and rotational behavior data were analyzed using a one-
way ANOVA, and post hoc analyses were carried out using Bonferonni-corrected multiple 
comparison tests. A two-way repeated measures ANOVA was used to analyze all other 
behavioral data. Post hoc analyses were performed using Bonferonni-corrected multiple 
comparison tests. 
2.4 Results 
Effect of casting prior to injury on effects of unilateral 6-OHDA on forelimb rearing and 
akinesia 
 Animals casted prior to 6-OHDA infusion showed reductions in forelimb 
asymmetry (Fig 2.1a) and akinesia (Fig 2.1b) normally associated with unilateral 6-OHDA 
toxicity. The casted sham group and non-casted sham group showed no significant difference in 
asymmetric behaviors, therefore these groups were pooled for further analysis (F(1,11) = 2.336; p 
>0.05). Analysis of variance indicated an overall group effect for forelimb asymmetry (F (2, 47) = 
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8.74; p < 0.01) and forelimb akinesia (F (2, 39) = 48.33; p < 0.01). Post hoc analysis of these 
behavioral measures indicated significant attenuation of asymmetric behavior in animals casted 
prior to infusion of 6-OHDA when compared with animals that received 6-OHDA alone (p < 
0.01).  
 
Effect of casting on apomorphine-induced turning normally associated with unilateral 6-
OHDA.  
 Casting-induced attenuation of the effects of 6-OHDA-induced forelimb rearing 
and akinesia might conceivably be caused by compensatory changes in pathways that parallel the 
nigrostriatal DA projection. Thus, we also used a third behavioral test, apomorphine-induced 
turning. This phenomenon depends on a large (>90%) reduction in the availability of DA at DA 
receptors (Ungerstedt, 1971). We observed that contralateral turning in response to apomorphine 
was markedly attenuated by casting prior to injury when compared to animals receiving a 6-
OHDA alone (F (2, 18) = 19.32; p < 0.01; Fig 2.2).  
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Figure 2.1a: Effects of prior forced limb use on forelimb use asymmetry after 6-OHDA. 
Unilateral casting of a forelimb prior to ipsilateral infusion of 6-OHDA into the MFB prevented the 
limb use asymmetry associated with unilateral 6-OHDA lesion. Sham-lesioned animals showed no 
asymmetry of limb use while animals receiving 6-OHDA into the MFB without a cast showed a 
significant asymmetry of limb use (* p<0.01 vs sham-lesioned animals). Animals that received a cast 
prior to 6-OHDA infusion displayed a significant decrease in limb use asymmetry  (* p<0.01 vs lesioned 
animals). All values are expressed as mean asymmetry score ± S.E.M.  
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Figure 2.1b: Effects of prior forced limb use on forelimb akinesia after 6-OHDA. Forelimb 
akinesia was prevented by unilateral casting prior to ipsilateral 6-OHDA infusion into the MFB. Sham-
lesioned animals showed no significant akinetic behavior. 6-OHDA-lesioned animals that were not fitted 
with a cast displayed significant akinetic behavior when compared to sham-lesioned animals (* p<0.01). 
This akinetic behavior was prevented in casted/lesioned animals (* p < 0.01, lesioned vs casted/lesioned) 
and comparable to behavior observed in sham-lesioned animals. All values are expressed as mean 
asymmetry score ± S.E.M.  
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Figure 2.2: Effects of prior forced limb use on apomorphine-induced rotational behavior 28 d after 6-
OHDA. Pre-6-OHDA forced limb use attenuated apomorphine-induced rotations. Sham-lesioned animals did 
not exhibit contralateral rotational behavior in response to apomorphine. 6-OHDA infusion increased the 
number of contralateral rotations in lesioned-animals (*p < 0.05, lesioned vs sham-lesioned). Forcing 
reliance on a forelimb prior to contralateral infusion of 6-OHDA greatly attenuated apomorphine-induced 
rotational behavior (* p < 0.05, lesioned vs casted/lesioned animals). All values are expressed as mean 
rotations ± S.E.M.  
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Effect of casting prior to injury on 6-OHDA-induced changes in DA and DOPAC in the 
striatum 
 There was no significant difference in striatal DA and DOPAC content between 
sham-lesioned animals and casted-sham-lesioned animals therefore data from these groups were 
pooled for further analysis (F (2, 2) = 1.276; p > 0.05). A one-way ANOVA revealed a significant 
group effect for both DA and DOPAC content [DA: (F (2, 18) = 10.03; p < 0.01); DOPAC: (F (2, 18) 
= 11.16; p < 0.01)]. 6-OHDA alone resulted in an almost complete loss of both striatal DA and 
DOPAC content compared to levels observed in sham-lesioned animals (Fig. 2.3; p < 0.01, 
shams vs. 6-OHDA alone). Post hoc analysis revealed a significant attenuation of the loss of 
striatal DA and DOPAC content in animals casted prior to 6-OHDA when compared to animals 
receiving 6-OHDA alone (p < 0.05). No significant changes in striatal DA or DOPAC content 
were observed between groups in the non-infused hemisphere relative. 
 
Effect of casting on striatal GDNF  
 Finally, we examined the profile of striatal GDNF protein levels during and after 
forced limb-use in Sprague Dawley animals that were not subjected to 6-OHDA. A one-way 
ANOVA revealed GDNF levels significantly increased in the striatum corresponding to the 
overused limb compared to non-casted control animals (F (2, 28) = 5.934; p < 0.01), whereas 
GDNF levels in the opposite hemisphere were unchanged. Post hoc analysis indicated this 
increase was time dependent, increasing significantly above control 24 hr and 3 days after 
placement of the cast (p < 0.05) and returned to near baseline levels on day 7 (Fig 2.4).  
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 Figure 2.3: Effects of prior forced limb use on striatal DA and its metabolites 30 d after 6-
OHDA. Animals in the lesioned group showed a significant loss of DA and DOPAC when compared 
with sham-lesioned (DA: 0.84 ± 3.6%, DOPAC: 11 ± 5%, lesioned values; p < 0.01) and 
casted/lesioned (DA: 47 ± 25%; DOPAC: 81 ± 21%; p < 0.05) animals. This loss was attenuated in 
casted/lesioned animals such that no significant difference was detected between sham-lesioned and 
casted/lesioned animals. All results are expressed as mean percent of control ± S.E.M., which were 2.7 
± 0.34 ng/ 20 μl for DA, 1.2 ± 0.16 ng/ 20 μl for DOPAC.  
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Figure 2.4: Effects of forced limb use on striatal GDNF levels. GDNF protein levels increased in a 
unilateral and time-dependent manner during unilateral casting. This increase was significant (* p<0.05) at 
72 hours after the cast was placed on the animal. The increase in GDNF was only observed in the striatum 
corresponding to the non-casted, overused limb. All results are expressed as a mean percent of contralateral 
side ± S.E.M., which was 0.31 ± 0.04 ng/mg wet tissue weight for GDNF.  
 
2.5 Discussion 
Unilateral infusion of 6-OHDA along the MFB causes degeneration of DA neurons in the 
ipsilateral substantia nigra and loss of striatal DA and DOPAC content. This loss of striatal DA 
produces a number of motor deficits that include a tendency to limit the use of the contralateral 
limb during rearing, contralateral akinesia, and contraversive turning in response to the systemic 
administration of apomorphine (Ungerstedt, 1971; Marshall and Ungerstedt, 1977; Schallert and 
Tillerson, 2000). In this study, we report three observations. First, placing a cast on an animal for 
7 days prior to the ipsilateral infusion of 6-OHDA prevented the development of behavioral 
deficits characteristic of this lesion model. Second, casting prior to injury greatly attenuated the 
loss of striatal DA. Third, casting prior to injury caused a significant but transient increase in 
striatal GDNF. These data extend our previous findings (Tillerson et al., 2001, 2002), indicating 
that casting the unimpaired forelimb for 7 days prior to and following 6-OHDA infusion protects 
against 6-OHDA toxicity.  
It is our assumption that the ability of casting to protect against the behavioral effects of 
6-OHDA results from the casting-induced attenuation of the loss of DA. The strongest support 
from this assumption comes from the ability of casting to greatly reduce the apomorphine-
induced rotation normally associated with unilateral 6-OHDA infusions into the nigrostriatal DA 
projections. Our working hypothesis is that the casting-induced attenuation of the loss of striatal 
DA was, in turn, a result of an exercise-induced increase in GDNF in the region that 
subsequently received 6-OHDA. The neuroprotective effects of GDNF are well known (see 
Introduction). Although GDNF had declined to baseline prior to 6-OHDA infusion, this does not 
preclude GDNF as a possible participant in the neuroprotective effects of forced limb-use. 
Indeed, previous investigators have shown that exogenous GDNF can be neuroprotective if 
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administered as much as 7 days prior to 6-OHDA (Kearns & Gash, 1995; Choi-Lundberg et al., 
1998), and in those experiments it is unlikely that levels of this trophic factor were still elevated 
at the time of toxin administration.  
To be effective, GDNF would need to act on its receptor complex, thereby initiating a 
signaling cascade that produces cytoplasmic and/or translational changes in DA neurons. It is 
possible that these downstream effects of GDNF are activated after the protein has returned to 
baseline levels. Moreover, extracellular signal regulated kinase (ERK), a downstream effector of 
GDNF, has been shown to be activated after exercise, and to remain elevated for up to one 
month (Shen et al, 2001) 
Although we have focused our initial attention on GDNF, there are many other factors 
that may play a role in the casting-induced protection that we observed. Exercise, primarily 
running, has been shown to increase brain derived neurotrophic factor (BDNF) and nerve growth 
factor (NGF) (Neeper et al., 1996), fibroblast growth factor-2 (FGF-2) (Gomez-Pinilla et al., 
1995), and insulin-like growth factor 1 (IGF-1) (Carro et al., 2001) in certain regions of the CNS, 
particularly the hippocampus. Although there are no previous reports on the effects of exercise 
on trophic factors in the striatum, each of these factors has potent trophic activity towards DA 
neurons (Hyman et al, 1991; Altar et al., 1992; Lin et al., 1993; Winkler et al., 1996) and, where 
examined, has been shown to protect against the neurotoxic effects of 6-OHDA (Hoffer et al., 
1994; Kearns & Gash, 1995; Levivier et al., 1995; Choi-Lundberg et al., 1998; Akerud et al., 
1999; Gong et al., 1999; Kramer et al., 1999; Schatz et al., 1999; Shults et al., 2000; Wang et al., 
2002). For example, rats exposed to enriched environments, exercise regimens, dietary 
restriction, and learning tasks all show an increase in protein and mRNA levels of trophic factors 
in the brain (Neeper et al., 1995; Gomez-Pinilla et al., 1998; Torasdotter et al., 1998; Pham et al., 
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1999; Duan et al., 2001; Young et al., 1999). Many of these environmental changes are 
protective against hippocampal damage incurred from insults, such as ischemia, and it has been 
proposed that this neuroprotection is driven by increases in trophic factors (Duan et al, 2001; 
Young et al, 1999). Moreover, it seems likely that more than one factor will ultimately be found 
to be responsible for exercise-induced protection. In this regard, we note that FGF-2, one of the 
trophic factors shown to be upregulated by exercise (Gomez-Pinilla et al, 1995), has also been 
shown in vitro to induce expression of both GDNF and BDNF (Suter-Crazzolara and Unsicker, 
1996; Kwon, 1997).  
In conclusion, these data suggest that forced limb-use is protective against subsequent 
injury to the nigrostriatal DA system and this protection is accompanied by increases in striatal 
GDNF. These findings provide further evidence that physical therapy may be beneficial to 
patients with PD, as well as the possibility that exercise throughout life may protect against 
development of PD. In fact, our group has recently shown that forced use is not only protective 
but that lack of use may exacerbate damage associated with 6-OHDA, indicating that motor 
weakness early in the disorder may be an exacerbating factor (Tillerson et al, 2002). As early 
detection methods are developed, physical activity may be an important factor in slowing or even 
halting the neurodegenerative cascade associated with PD.  
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 3.0 Effects of forced limb use on the vulnerability of dopamine neurons 
to 6-hydroxydopamine 
 
3.1 Abstract 
Unilateral infusion of 6-OHDA into the MFB of the adult rat causes contralateral motor 
deficits and decreases in the apparent number of DA cell bodies and terminals in the SN and 
striatum, respectively. However, we have previously shown that casting of the ipsilateral 
forelimb for 7 days prior to 6-OHDA, causing forced use of the contralateral forelimb, 
significantly reduces this apparent neurodegeneration. It remains unknown, however, if the 
protection from 6-OHDA-induced depletion of striatal DA reflects a decrease in the vulnerability 
of SN neurons to 6-OHDA, a regeneration of processes after partial injury, or sprouting from 
undamaged axons into a region of DA terminal loss. In this report we show that animals casted 
prior to 6-OHDA infusion showed significant attenuation of normal toxin-induced loss of both 
tyrosine hydroxylase immunoreactive and Nissl-stained cells in the SN. Precasted animals also 
showed a significant sparing of tyrosine hydroxylase positive terminals in the striatum. These 
data suggest that prior forced limb use produces behavioral and neurochemical protection by 
decreasing the vulnerability of DA neurons to oxidative stress. 
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3.2 Introduction 
PD is a progressive neurodegenerative disorder of unknown etiology that results in the 
loss of DA neurons projecting from SN to striatum. The most common treatments for PD focus 
on alleviating symptoms of the disorder by temporarily restoring dopaminergic tone in the 
striatum. However, these treatments do not appear to reduce the progression of the disease. 
Moreover, side effects of these treatments gradually emerge and efficacy usually is reduced 
(Pahwa and Lyons, 2004). Thus, developing strategies for slowing or preventing ongoing 
degeneration or even reversing the neurodegenerative process in PD is of paramount 
importance.  
It is well established that exercise regimens after ischemic insult can produce functional 
recovery following brain injury. Constraining the non-impaired upper extremity in stroke 
patients, thereby forcing use of the impaired limb, improves motor function (Taub et al., 1999; 
Liepert et al., 2000; Taub and Morris, 2001; Sterr et al., 2002). Additionally, exercise and 
enriched environments prior to injury have been shown to be neuroprotective in animals 
subjected to a variety of neurotoxic conditions, including ischemia, (Stummer et al., 1994, Li et 
al., 2004), 3-acetylpyrine, domoic acid, (Carro et al. 2001), and genetic modifications associated 
with Alzheimer’s disease (Adlard et al., 2005; Jankowsky et al., 2005; Lazarov et al., 2005). 
Recent evidence suggests that exercise can be neuroprotective in PD as well. Increases in 
physical activity levels throughout life have been associated with a lower propensity to develop 
PD (Sasco et al., 1992; Tsai et al., 2002; Hirsch et al., 2003; Chen et al., 2005). There is also 
evidence for efficacy of physical therapy regimens in the treatment of PD (Toole et al., 1999, 
Bergen et al., 2002). Animal models provide further support for the hypothesis that exercise can 
be neuroprotective against PD. For example, treadmill and exercise in a running wheel, as well 
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as an enriched environment, has been shown to reduce the effects of another DA-selective 
neurotoxin, MPTP in a mouse model (Bezard et al., 2003; Tillerson et al., 2003; Faherty et al., 
2005). Our own research has focused on the use of 6-OHDA to produce models of DA 
deficiency. Using a unilateral 6-OHDA rat model, we and our colleagues have recently shown 
that placing a cast on one forelimb for 7 days immediately prior to or following the unilateral 
administration of 6-OHDA can attenuate both the behavioral and neurobiological effects of the 
toxin (Tillerson et al., 2001; 2002; Cohen et al., 2003). However, it is not known in any of these 
cases whether the apparent neuroprotection reflects a decrease in the vulnerability of DA 
neurons to the toxin, a regeneration of damaged DA axons, or the sprouting of DA axon 
terminals from non-damaged neurons into areas initially affected by the toxin. Therefore, in the 
present study we have examined the profile of cell loss and degeneration of DA neurons and 
terminals in the nigrostriatal pathway over time in response to forced limb use followed by 
infusion of 6-OHDA into the MFB in adult rats. Our results suggest that exercise acts to reduce 
the vulnerability of DA neurons to the toxin. 
 
3.3 Materials and Methods 
Animals 
Male Sprague Dawley rats (Hilltop Lab Animals, Scottdale, PA) weighing 300-400 
grams were used throughout these experiments. All animals were housed two per cage and 
maintained on 12 h light/dark cycle with food (Purina lab chow) and water available ad libitum. 
All procedures were in strict accordance with the guidelines for the NIH Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at 
the University of Pittsburgh.  
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 Preoperative and Surgical Procedures 
Seven days prior to surgery animals were randomly assigned to one of four groups: 
unilateral, intracerebral vehicle injection (n = 6), vehicle injection proceeded by a forelimb cast 
(n = 6), unilateral infusion of 6-OHDA alone (n = 14), and 6-OHDA proceeded by a forelimb 
cast (n = 13). Animals in the two casted groups were fitted with plaster of Paris casts to 
immobilize the right forelimb in a naturally retracted position against the sternum (Jones and 
Schallert, 1994; Cohen et al., 2003). After the seven days, all animals were anesthetized with 
Equithesin (25 mg/kg pentobarbital and 150 mg/kg chloral hydrate, i.p.), the casts were removed 
(if present), and the animals were prepared for surgery. Thirty minutes prior to surgery, animals 
were given desipramine (25 mg/kg, i.p.), an inhibitor of norepinephrine uptake that serves to 
block the entry of 6-OHDA into noradrenergic neurons. 6-OHDA (Sigma, St. Louis, MO; 3 µg 
in 2 µl of 0.9% NaCl, 0.02% ascorbic acid) or vehicle was infused (0.5 µl/min) into the right 
MFB (- 4 mm posterior, - 2.0 mm lateral of bregma, and 8 mm ventral to dura, according to the 
atlas of Paxinos and Watson (1982).  
 
Behavioral Analysis 
 A separate group of animals was examined to determine if forced limb use produces an 
increase in use of the non-casted forelimb. Animals were videotaped in their home cage during 
their awake (dark) cycle for a five minute period, the videotapes were the analyzed, and right, 
left and both forelimb movements were counted (Schallert and Tillerson, 2000). After the first 
night of testing, animals were anesthetized with Equithesin and randomly divided into two 
groups, one group (n = 6) was fitted with a plaster of Paris cast and the second group (n = 5) was 
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allowed to use both forelimbs freely.  Animals were then videotaped 2, 3, 5, and 6 days after 
placement of the cast.  
 
Histological Analysis 
 At 2, 7, or 28 d post-infusion, animals were deeply anesthetized with Equithesin and 
sacrificed via transcardial perfusion using ice cold 0.9% saline followed by 4% 
paraformaldehyde. Brains were then sectioned at 60 microns using a cryostat. Every fifth section 
cut from the SN and striatum was collected for labeling with the antiserum for tyrosine 
hydroxylase (TH) or Nissl substance and sections from each group were processed together.  
TH+ immunoreactivity All sections were rinsed 3 times in 10 mM phosphate buffered 
saline (PBS) prior to and between each incubation. The sections were pretreated for 15 min with 
3% H2O2 in 10 mM PBS followed by blocking for 1 hr with 5% normal goat serum and then 
incubated overnight at 4ºC in a 1:1000 dilution of mouse anti-TH antibody (Chemicon Inc, 
Temecula, CA; Cat # MAB318) in normal goat serum. This was followed by incubation for 1 hr 
at room temperature in a 1:200 dilution of biotinylated goat anti-mouse secondary antibody 
(Jackson ImmunoResearch, West Grove, PA). Tissue was then treated with avidin biotin 
peroxidase complex (ABC-Elite, Vector Laboratories, Burlingame, CA) with 3, 3-
diaminobenzadine as the chromagen to visualize the reaction. Sections were then mounted on 
gelatin coated slides, dehydrated in ascending concentrations of ethanol and coverslipped with 
Permount mounting medium (Fisher Scientific, Pittsburgh, PA). 
Nissl substance: Nissl-positive cells were stained using a solution of 10% thionin 
(Sigma, St. Louis, MO). Sections were dehydrated through increasing concentrations of ethanol, 
defatted in chloroform and rehydrated through decreasing concentrations of ethanol. Sections 
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were then placed in thionin for 45 sec and rinsed in increasing concentrations of ethanol and 
coverslipped with Permount mounting medium (Fisher Scientific, Pittsburgh, PA).  
 
Image Analysis 
 Densitometry in striatum: Densitometric analysis was performed in the striatum using a 
M5 MCID system (Imaging Research Inc., Ontario, Canada). For quantification of TH+ staining, 
the entire striatum was visualized under the camera and then analyzed for density of pixels 
present in each striatum.  
Stereology in SN: For stereological analysis of cell counts in the SN, every third section 
from each animal was randomly selected for staining using a random number generated from a 
computer program. We then used systematic random sampling (using the fractionator approach) 
to determine cell number estimates using Stereoinvestigator software coupled to Microvid 
systems (Microbrightfield Inc.) (e.g., Pierri et al., 2001; Volk et al., 2001). 
 
Statistical Analysis 
Data were analyzed with a one-way ANOVA, using Bonferonni-corrected multiple 
comparison tests for post hoc analysis. There was no significant difference between striatal or 
nigral measures in the two vehicle treated groups (vehicle-injected with or without a cast). 
Therefore these groups were pooled for further analysis (striatum: F (3, 2) = 4.395; p >0.05; SN: F 
(3, 2) = 3.639; p > 0.05). No significant changes in cell number or terminal density were observed 
between groups in the non-infused hemisphere in any measures. All comparisons were made to 
vehicle treated animals.  
 
 39 
3.4 Results 
Effect of forced limb use on limb use in the home cage 
 In order to determine if forced limb use produced an increase in limb use, we 
monitored behavior in the home cage in casted and uncasted animals. Over the 7 d observation 
period, normal animals placed their right and left forelimbs on the wall of the home cage 
approximately 15 times in 5 min. When casted animals were observed 2d after placement of the 
cast there was a significant decrease in the number of left, as the right limb was constrained, 
forelimb placements (3.3 ± 0.7 placements, p<0.001, Fig 3.1). By 3 d after placement of the cast, 
animals began to use their single forelimb as much as non-casted animals used both forelimbs. 
As a result, there was no significant difference in limb use. This increased use of the uncasted 
limb persisted for the 6-day period examined. 
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Figure 3.1: Effects of unilateral casting on limb placements in the homecage. Animals in the 
casted group showed a significant decrease (p<0.001) in placements of the non-casted forelimb at 2d 
after placement of the cast that was attenuated by 3d post-cast. By 3d post –cast casted animals were 
using their non-casted forelimb to the same degree that non-casted animals used both forelimbs.  
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 Effect of forced limb use on the 6-OHDA-induced loss of TH+ terminals in the striatum  
 Neither the sham nor the precast groups exhibited any significant difference in 
striatal TH+ density at 2, 7 and 28 d (p > 0.05). In contrast, a significant difference in striatal TH+ 
density was revealed between animals treated with 6-OHDA alone and sacrificed at 2 d and 
those sacrificed at 7 and 28 d (p < 0.001). Although TH+ was unaffected by 6-OHDA at 2 d 
postoperative (n = 4), animals treated with 6-OHDA alone (n = 5) had a 65.3± 3.9% loss of TH 
immunoreactivity (TH+) in the striatum at 7 d postoperatively when compared to vehicle treated 
animals (n = 8) who showed no loss of TH. This loss of TH was sustained at 28 d with animals 
receiving 6-OHDA alone (n=5) showing a 71.1 ± 9.1% (p < 0.001; Fig 3.2). Forced limb use 
prior to infusion of 6-OHDA (n = 9) significantly reduced the loss of TH observed as a result of 
6-OHDA alone (p < 0.001) such that there was no difference between these animals and vehicle 
treated control animals at either 7 or 28d (0.0 ± 7.9 vs. 0.0 ± 11.0%, ns). [Overall group effect: (F 
(8, 25) = 14.3; p < 0.0001; Fig 3.2] 
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Figure 3.2: Effects of unilateral casting on TH+ terminals in the striatum after 6-OHDA. 
Loss of TH was prevented by casting of a forelimb prior to subsequent ipsilateral 6-OHDA 
infusion into the MFB. Sham animals showed no significant loss of TH. 6-OHDA animals that 
were not fitted with a cast displayed significant loss of TH when compared to sham animals (* 
p<0.01). This loss was prevented in casted/6-OHDA treated animals (* p < 0.01), 6-OHDA vs 
casted/6-OHDA). All values are expressed as percent loss of TH+ density (± SEM) compared to 
control animals.  
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 Effect of forced limb use on the 6-OHDA-induced loss of TH+ neurons in the SN  
 Animals treated with 6-OHDA alone (n=10) showed an 86.6 ± 4.4% loss of TH+ 
cells in the SN at 7 and 28 d after 6-OHDA alone when compared to a 0.0 ± 3.26% loss in 
vehicle treated animals (n = 8). Animals exposed to forced limb use prior to 6-OHDA (n=9) 
showed a significant reduction in loss of TH+ cells in the SN (5.6 ± 10.5%; p <0.001) when 
compared to 6-OHDA alone. Additionally, both the sham and precast groups showed no 
significant difference in the number of TH+ neurons across 2, 7 and 28 d (p>0.05) while a 
significant difference in the number of TH+ neurons was revealed between animals treated with 
6-OHDA alone and sacrificed at 2d (62.2 ± 14.5) and those sacrificed at 7 (12.9 ± 2.4) and 28 d 
(13.4 ± 10.5) (p<0.001). [Overall group effect: 7 d (F (2, 13) = 49.6; p < 0.001); 28 d (F (2, 12) = 
137.8; p < 0.001) Fig 3.3a&b] 
Effect of forced limb use on the 6-OHDA-induced loss of Nissl positive neurons  
 6-OHDA induced loss of TH+ cells in the SN could be a result of a loss of the TH 
phenotype rather than the degeneration of the terminal itself. Therefore, we examined the 
number of Nissl+ cells in the SN. A significant loss of Nissl+ cells was observed at 7 and 28 d 
after 6-OHDA alone (n=10) when compared to vehicle treated animals (42.8 ± 6.2%; p<0.001). 
Casting prior to 6-OHDA (n=9) completely blocked cell loss (0.0 ± 4.1%) showing a significant 
difference from animals treated with 6-OHDA alone (p<0.001). A comparison of animals treated 
with vehicle alone (n=8) and those casted prior to 6-OHDA revealed no significant change in the 
number of Nissl+ positive cells (p>0.05). Finally, there were no differences in any groups across 
2, 7, and 28 d. [Overall group effect: 7 d (F (2, 13) = 80.4; p < 0.001; 28 d (F (2, 13) = 12.5; p < 0.01) 
Fig 3.4a&b] 
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Figure 3.3a: Photomicrographs of TH+ cells in the SN. Sham animals (a) showed no 
loss of TH+ cells, while 6-OHDA treated animals showed little loss of TH+ cells at 2d post-6-
OHDA (b and arrow) and a significant loss at 28d post-6-OHDA (c). (D) Animals casted prior 
to 6-OHDA showed no loss of TH+ cells at 2d post-6-OHDA and a significant attenuation at 
28d post 6-OHDA (e).  
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Figure 3.3b: Effects of unilateral casting on loss of TH+ cells in the SN after 6-OHDA. Pre-6-OHDA 
forced limb use attenuated loss of TH+ cells in the SN. Sham animals had no detectable loss of TH+ cells in 
the SN. 6-OHDA infusion significantly decreased the number of cells in the SN at 7 and 28 days post 
infusion in 6-OHDA treated animals (*p < 0.001, 6-OHDA vs sham). Forcing reliance on a forelimb prior 
to contralateral infusion of 6-OHDA greatly attenuated loss of TH+ cells in the SN (* p < 0.001, 6-OHDA vs 
casted/6-OHDA animals). All values are expressed as percent cell loss (compared to controls) ± S.E.M. 
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Figure 3.4a: Photomicrographs of Nissl+ cells in the SN. Sham animals (a) showed no 
loss of nissl+ cells, while 6-OHDA treated animals showed non-significant loss of Nissl+ cells 
at 2d post-6-OHDA (b) and a significant loss at 28d post-6-OHDA (c). (D) Animals casted 
prior to 6-OHDA showed an attenuation loss of TH+ cells at 2d post-6-OHDA and a 
significant attenuation at 28d post 6-OHDA (e).  
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Figure 3.4b: Effects of unilateral casting on loss of Nissl+ cells in the SN. Animals in the 6-OHDA 
group showed a significant loss of Nissl+ cells in the SN when compared with sham (p < 0.01) and casted/6-
OHDA animals (p < 0.01) animals. This loss was attenuated in casted/6-OHDA animals such that no 
significant difference was detected between sham and casted/6-OHDA animals. All results are expressed as 
mean percent of control ± S.E.M.  
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 3.5 Discussion 
Current treatments for PD, such as L-dopa, only alleviate the symptoms of the disease 
and can lose their efficacy over time (Pahwa and Lyons, 2004). Thus, it is important that new 
therapeutic approaches that slow or block the neurodegenerative process be explored. One such 
approach is exercise. Exercise has been known for some time to have beneficial effects on the 
brain (for review see Mattson, 2000) but until recently was not widely explored in the treatment 
of PD. We have previously shown that forced exercise prior to 6-OHDA protects from both the 
behavioral and neurochemical effects of the toxin (Cohen et al., 2003). However, it remained 
unknown if this apparent neuroprotection was a result of sparing of nigrostriatal DA neurons and 
terminals or of sprouting of remaining neurons into areas primarily affected after administration 
of 6-OHDA. The present study was undertaken to more directly determine if forced limb use 
prior to 6-OHDA protects DA neurons from the toxic effects of 6-OHDA or if it stimulates 
sprouting in unaffected neurons following 6-OHDA.  
We used immunohistological analysis to determine the effect of prior forced limb use on 
TH immunoreactive terminals and cells in the striatum and SN respectively after 6-OHDA 
toxicity. Previous studies have shown that a toxic insult such as MPTP or 6-OHDA can result in 
a loss of the TH phenotype without loss of actual DA neurons (Jackson-Lewis et al., 1995; Ara et 
al., 1998; Rosenblad et al., 2003). Thus, to distinguish between actual cell death and loss of the 
TH phenotype in the SN, we stained serial sections in the SN with TH or Nissl. After 6-OHDA 
treatment, a significant loss of TH+ cells was observed by 7 days post-infusion, and persisted at 
least to 28 days. Additionally, 6-OHDA caused a similar loss of cells positive for Nissl substance 
indicating that 6-OHDA produces cell death in the SN rather than only a loss of the TH 
phenotype in these neurons. However, forced limb use blocked both the loss of TH+ cells and 
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cells positive for Nissl substance at 7 and 28 d  after infusion of 6-OHDA. These data support the 
hypothesis that forced limb use for the 7 d prior to 6-OHDA infusion prevents degeneration in 
the nigrostriatal DA system 
We also observed that prior forced limb use prevents the loss of TH+ terminals in the 
striatum. 6-OHDA caused a significant loss of TH+ terminals in the striatum that was not 
detectable 2 d after 6-OHDA infusion but was complete by 7 d post-infusion. In contrast, 
animals exposed to prior forced limb use and 6-OHDA showed no sign of loss of TH+ terminals 
in the striatum over a 28 d period. These data are in agreement with our previous finding in 
which we observed a protection of striatal DA content at 4 wks in 6-OHDA treated animals that 
underwent prior forced limb use. The sparing of DA terminals in the striatum further suggests 
that forced limb use confers a resistance of the nigrostriatal DA system to the effects of 6-
OHDA.  
In order to determine if casting a forelimb increases the use of the non-casted forelimb, 
we observed casted and non-casted animals in their home cage during the casting period. We 
determined that 2 d after placement of the cast, casted animals used their forelimb significantly 
less than non-casted animals. However, this effect was attenuated by 3 d post-cast. Indeed, not 
only did casted animals begin to use their non-casted limb as much as the corresponding limb of 
non-casted animals but also they began to use the non-casted limb as much as non-casted 
animals used both forelimbs. These data indicate that the protective effects of forced limb use 
could function through an increase in use of the non-casted forelimb.  
The neuroprotective effects of forced limb use on TH in the nigrostriatal system and cell 
survival in the SN are consistent with our previous observations demonstrating the 
neuroprotective effects of prior forced limb use on DA levels in the striatum and behavior 
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(Cohen et al., 2003). Protection of behavior and DA content also has been observed with prior 
exposure to enriched environment and/or a running wheel in mice (Bezard et al., 2003; Faherty 
et al, 2004), casting following 6-OHDA in rats (Tillerson et al., 2001; 2002), and treadmill 
running following MPTP in mice (Tillerson et al., 2003). Collectively they demonstrate that 
under our conditions behavioral protection from 6-OHDA can be associated with protection of 
both DA neurons in the SN and DA content within striatal terminals.  
Several other groups have demonstrated exercise-induced protection from the behavioral 
effects of MPTP and 6-OHDA. However, in some instances DA neurons have not been directly 
examined (Fisher et al., 2004; Mabandla et al., 2004; Howells et al., 2005). Moreover, in one 
case in which DA neurons have been examined, no protection was observed (Poulton & Muir, 
2005). These data raise the possibility under some conditions preservation of DA terminals is not 
crucial for the protection of behavior after a toxic insult to the DA system. Although alternative 
explanations have not been carefully explored, compensatory changes in residual DA neurons 
have been proposed to underlie the ability of animals to sustain partial DA loss without severe 
behavioral consequences (Zigmond, 2000); perhaps exercise can promote such compensations 
under some circumstances. It is possible that exercise may stimulate remaining DA neurons to 
function at a higher than normal level in order to prevent behavioral consequences that would 
normally be associated with the level of loss of DA neurons observed.  
Our working hypothesis is that the casting-induced attenuation of the loss of DA neurons 
and terminals was, in turn, a result of an exercise-induced increase in trophic factors in the 
nigrostriatal bundle. Indeed, we have shown that forced limb use increases GDNF in the striatum 
associated with the overused forelimb (Cohen et. al., 2003). Additionally, exercise, primarily 
running, has been shown to increase trophic factors in certain regions of the CNS, particularly 
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the hippocampus (Gomez-Pinilla et al., 1995, 1998; Neeper et al., 1996; Carro et al., 2001; 
Faherty et al., 2005). Whereas multiple forms of exercise have been shown to increase trophic 
factors in various parts of the brain our paradigm is unique in several ways. First, we have shown 
that forced limb use not only increases GDNF in the striatum corresponding to the “exercised” 
forelimb but also confers protection from the behavioral, neurochemical, and neuroanatomical 
effects of a 6-OHDA infusion. Second, forced limb use differs from other types of exercise, such 
as treadmill running, in its duration and intensity possibly explaining the difference in 
neuroprotection conferred. These factors have potent trophic activity towards DA neurons 
(Hyman et al, 1991; Altar et al., 1992; Lin et al., 1993; Winkler et al., 1996) and, where 
examined, has been shown to protect against the neurotoxic effects of 6-OHDA (Hoffer et al., 
1994; Kearns & Gash, 1995; Choi-Lundberg et al., 1998; Akerud et al., 1999; Gong et al., 1999; 
Schatz et al., 1999; Shults et al., 2000; Wang et al., 2002). Although it has been widely shown 
that exercise increases trophic factor production, it is unknown how exercise functions to 
stimulate trophic factor production. Moreover, although, trophic factors provide a promising 
target for the neuroprotective effects of exercise, the relationship is correlative. Further 
experiments examining the casual relationship between increases in trophic factors and the 
neuroprotective effects of exercise need to be performed before further conclusions can be 
drawn.  
Although we have chosen to mainly focus on increases in trophic factors as the 
mechanism for forced-limb use induced neuroprotection, there are other factors that may play a 
role. First, although forced limb use has positive effects on the brain, it also can be regarded as a 
form of restraint stress and thus, would be expected to stimulate the hypothalamic-pituitary-
adrenal (HPA) axis. Normally conceived of as neurotoxic, stress can also have neuroprotective 
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effects (Sloviter et al., 1989; Chadi et al., 1993; Follesa and Mocchetti, 1993; Mocchetti et al., 
1996; Sousa et al., 1999). It is possible, therefore, that the HPA axis plays a pivotal role in forced 
limb use protection through stimulated neurotrophic factor expression or through the production 
of melanocortins, both of which have been shown to have neuroprotective effects in various 
peripheral and central nervous system injury models (Sloviter et al., 1989; Chadi et al., 1993; 
Follesa and Mocchetti, 1993; Mocchetti et al., 1996; Sousa et al., 1999).  
There are many other factors that may play a role in the casting-induced protection that 
we observed. Exercise, primarily running, has been shown to increase brain derived neurotrophic 
factor (BDNF) and nerve growth factor (NGF) (Neeper et al., 1996), fibroblast growth factor-2 
(FGF-2) (Gomez-Pinilla et al., 1995), and insulin-like growth factor 1 (IGF-1) (Carro et al., 
2001) in the CNS, particularly the hippocampus. Although we have focused on GDNF, it seems 
likely that more than one factor will ultimately be found to be responsible for exercise-induced 
protection. It is important to note here that FGF-2, one of the trophic factors shown to be 
upregulated by exercise (Gomez-Pinilla et al, 1995), has also been shown in vitro to induce 
expression of both GDNF and BDNF (Suter-Crazzolara and Unsicker, 1996; Kwon, 1997).  
Although forced-limb use has been shown to be clinically therapeutic in other conditions 
(Taub et al., 1999; Liepert et al., 2000; Taub and Morris, 2001), it is not clear if forced-limb use 
would be ideal for PD patients. Although the disease often begins with unilateral manifestations, 
it typically progresses to a bilateral disorder. On the other hand, the positive effects that others 
have had with bilateral forms of exercise in experimental animals and in patients support the 
hypothesis that exercise regimens can be used as a therapy.  
In conclusion, these data suggest that forced limb-use is protective against subsequent 
injury to the DA neurons and terminals in the nigrostriatal system. These data are the first to 
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show that the protective effects of forced limb use are likely mediated by a protection of DA 
cells in the SN from the neurotoxic insult of 6-OHDA. Further exploration of the neuroprotective 
effects of forced limb use on a 6-OHDA model can provide targets for develop of 
neuroprotective drugs to treat PD, as well as lend support to the use of physical therapy as part of 
the treatment regimen for PD.  
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4.0 Effects of GDNF on the response of dopamine neurons to 6-
hydroxydopamine:  Time course of changes in phenotypic markers 
4.1 Abstract 
6-OHDA causes motor deficits and loss of DA cells of the SN and of their terminals in 
the rat striatum. GDNF can protect these neurons from the neurotoxic effects of 6-OHDA. 
However, there has been little exploration of the effects of GDNF on the temporal profile of 
phenotypic markers of the nigrostriatal pathway. Because the expression of phenotypic markers 
can be altered in response to injury, it is important to determine the profile of these markers in 
order to avoid incorrectly interpreting loss of phenotype. Thus in the present study, we explore 
the effects of GDNF on 6-OHDA neurotoxicity during the 8 wk period following administration 
of the toxin. Fluoro-gold (FG) was administered into a region located roughly in the middle of 
the striatum in order to label the cells projecting to this area. One week later, GDNF (9 μg) or 
vehicle was injected into this same site, followed 6 hrs later by 6-OHDA (4 μg) or its vehicle, 
When SN was examined 2-8 wks after 6-OHDA treatment, the toxin had caused a 83% loss of 
FG cells and a comparable loss of dopaminergic markers. The loss of FG cells was completely 
blocked by GDNF. In contrast, GDNF produced no significant protection of TH 
immunoreactivity in these FG-labeled cells at 2 wks, by 4 wks TH loss had reduced to 28%, (p 
>0.01) and by 8 wks no significant loss was observed (p > 0.01). Recovery of tyrosine 
hydroxylase terminals and the high affinity DA transporter in the striatum followed a similar 
time course to the SN, the vesicular monoamine transporter was largely recovered within 4 wks 
(30% loss). Striatal DA showed the greatest and fastest GDNF-induced recovery, reaching 
normal levels within 2 wks. Thus, whereas GDNF blocks the degeneration of DA neurons, full 
restoration of the DA phenotype occurs gradually over several weeks.  
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4.2 Introduction 
PD is a progressive neurodegenerative disorder of unknown etiology that results in the 
loss of DA neurons projecting from the SN to the striatum. Loss of dopaminergic tone in the 
striatum leads to a variety of neurological deficits, including resting tremor and akinesia. 
Current treatments for PD alleviate the symptoms of this disorder by temporarily restoring this 
dopaminergic tone and do nothing to slow or halt the degenerative process. Approximately 
60,000 individuals a year are diagnosed with PD in the U.S. and 85% of this group is over the 
age of 50. Thus, as the population ages, developing strategies for slowing or preventing ongoing 
degeneration or even reversing the neurodegenerative process in PD are of paramount 
importance.  
One promising therapy is the administration of trophic factors, such as glial cell line-
derived neurotrophic factor (GDNF). GDNF is a dimeric protein that is highly expressed in the 
developing rat striatum (Stromberg et al., 1993). It has been shown to be a potent survival factor 
for DA neurons (Lin et al., 1993), and exogenous administration of GDNF or a viral vector 
containing the GDNF gene can protect DA neurons from the neurotoxic effects of 6-OHDA in 
vitro (Kramer et al, 1999; Gong et al., 1999; Schatz et al., 1999) and the behavioral and 
neurotoxic effects in vivo (e.g. Hoffer et al., 1994; Kearns & Gash, 1995; Choi-Lundberg et al., 
1998; Smith et al., 2005). Although levels of GDNF are decreased in the brain during 
adulthood, injury to the brain can cause increases in the levels of GDNF (Naveilhan et al., 1997; 
Liberatore et al., 1997; Sakurai, et al., 1999; Wei et al., 2000; Smith et al., 2003) which may 
serve as a compensatory survival mechanism. However, even lower levels of GDNF are 
observed in patients with PD as compared to age-matched controls, which suggest that loss of 
trophic support may be a causal factor in the genesis of the disease (Siegel and Chauhan 2000). 
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Therefore, GDNF is a prime candidate as a therapeutic treatment against degeneration of the 
nigrostriatal DA system in PD.  
Here, we explore the effects of GDNF on 6-OHDA neurotoxicity at 2 wk intervals during 
the 8 wk period following administration of the toxin, using several phenotypic markers of the 
nigrostriatal system, and a non-DA cellular marker for two principle reasons. First, we wanted 
to characterize the time course for the neuroprotective effects of GDNF because most studies to 
date have examined the effects of GDNF on 6-OHDA after an extended period, thus we know 
little about how quickly this protection develops. Second, we wanted to follow the time course 
of TH, dopamine transporter (DAT) and the vesicular monoamine transporter 2 (VMAT2), as 
there has been little comparison of the differential protective effects of GDNF on these 
phenotypic markers of the nigrostriatal pathway. This aspect of this study could become quite 
important in a clinical setting where ligands for phenotypic markers are used in imagining 
studies to assess disease progression.  
 
4.3 Materials and Methods 
 
Animals 
Male Sprague Dawley rats (Hilltop Lab Animals, Scottdale, PA) weighing 250-350 
grams were used in these experiments. All animals were housed two per cage and maintained on 
12 h light/dark cycle with food (Purina lab diet) and water available ad libitum. All procedures 
were in strict accordance with the guidelines for the NIH Care and Use of Laboratory Animals 
and were approved by the Institutional Animal Care and Use Committee at the University of 
Pittsburgh.  
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 Surgical Procedures 
Seven days prior to GDNF and 6-OHDA infusion animals were anesthetized with 
isofluorane (1-2% in 100% O2, Inhaled; Halocarbon, River Edge, NJ), and Fluoro-gold (FG) 
(Fluorochrome, Denver, CO; 2% in sterile saline; 0.2 µl; 0.05 µl/min) was infused into the right 
striatum (+0.7 mm anterior, - 3.1 mm lateral of bregma, and 6.0 mm ventral to dura), according 
to the atlas of Paxinos and Watson (1982). One week after FG infusion animals were deeply 
anesthetized with isofluorane and 9 µg GDNF (Amgen, Thousand Oaks, CA) in 3 µl or vehicle 
(citrate buffer, pH 7.2) was infused into the right striatum at 0.5 µl/min at the same coordinates 
as FG. Six hours following GDNF administration animals were again deeply anesthetized with 
isofluorane and 6-OHDA (4 µg/0.75 µl; Regis, Morton Grove, IL) or vehicle (0.02% ascorbate in 
sterile saline; Sigma, St. Louis, MO) was infused into the right striatum at the same coordinates 
as above. 
 
Histological Analysis 
 At 2, 4, or 8 wks post-infusion, animals were deeply anesthetized with Equithesin and 
sacrificed via transcardial perfusion using ice cold saline followed by 4% paraformaldehyde in 
0.1 M phosphate buffer, pH 7.6. Following 48 hr cryoprotection in 30% sucrose, brains were 
sectioned at 60 μm on a cryostat at -20°C. Coronal slices were collected in a one-in-six series. 
Every sixth section cut from the SN was labeled and every sixth section from the striatum was 
labeled for TH, the vesicular monoamine transporter 2 (VMAT2), dopamine transporter (DAT), 
and GDNF. 
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Immunohistochemistry: All sections were rinsed 3 times in 10 mM phosphate buffered 
saline, pH 7.6 (PBS) prior to and between each incubation. PBS with 0.3% triton-X 100 was 
used as the diluent for all treatments unless specified otherwise. Sections were pretreated for 15 
min with 1% H2O2 in PBS followed by blocking for 1 hr with 10% normal donkey serum. 
Primary antibody incubations occurred on a rotator overnight at 4ºC using a 1:1000 dilution of 
mouse anti-TH antibody (Chemicon Inc, Temecula, CA, Cat# MAB318); a 1:250 dilution of goat 
anti-VMAT2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, Cat# SC7721); a 1:500 
dilution of rat anti-DAT antibody (Chemicon Inc, Temecula, CA, Cat# MAB369); or a 1:1000 
dilution of a goat anti-GDNF antibody (R&D systems, Minneapolis, MN, Cat# AF-212-NA)   
with 1% of the appropriate normal serum. This was followed by incubation for 1 hr at room 
temperature in a 1:200 dilution of the appropriate biotinylated secondary antibody (Jackson 
ImmunoResearch, West Grove, PA). Tissue was then treated with avidin biotin peroxidase 
complex (ABC-Elite, Vector Laboratories, Burlingame, CA) and subsequently with 0.02% 3, 3-
diaminobenzadine as the chromogen. Sections were then mounted on gelatin coated slides and 
dehydrated in ascending concentrations of ethanol before being rinsed in xylenes and 
coverslipped with Permount mounting medium (Fisher Scientific, Pittsburgh, PA). 
Double immunofluorescent labeling in SN: To visualize FG and TH in the same 
neurons, immunofluorescent labeling was utilized. Sections were treated with 10% normal goat 
serum for 1 hr and then incubated overnight at 4ºC in a 1:1000 dilution of mouse anti-TH 
antibody. Sections were subsequently labeled with Alexafluor 486 (goat anti-mouse; Molecular 
Probes, Invitrogen, CA) at a concentration of 1:500 in PBS for 2 hrs at room temperature, 
washed, mounted, coverslipped in DPX mounting medium (Fisher Scientific, Pittsburgh, PA), 
and viewed under epifluorescent illumination on a Nikon Inverted Eclipse TE microscope.  
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 Image Analysis 
 Non-immunoreactive area in striatum: Non-immunoreactive area analysis was 
performed in the striatum using MetaMorph software (Molecular Devices Corp., Downington, 
PA). For quantification of area devoid of immunoreactivity, the entire coronal section was 
visualized using a Nikon supercool scanner (Nikon Inc., Melville, NY). Images were then 
pseudo colored in MetaMorph and the region of low staining intensity on the three sections 
exhibiting the largest loss was circumscribed in blind fashion and the area within this region was 
calculated as mm2 by MetaMorph. The average of these three sections was used as a 
representation of non-immunoreactive area for a given animal.  
Cell counts in SN: For cell counts in the SN, one of every six sections from each animal 
was randomly selected for staining determined by randomly selecting number generated from a 
computer program. We then counted all FG+, TH+, and co-labeled cells in three sections of the 
SN.  
 
HPLC Analysis 
Animals were sacrificed via decapitation and a 2 mm section of striatum was dissected, 
centered around the track made by prior injections. Dissected striata were assayed using minor 
modifications of previous methods (Smith et al., 2002). Striatal tissue was suspended in 0.1 M 
HClO2 containing 347 μM NaHSO3 and 134 μM Na2 EDTA, homogenized in a volume 20 times 
(µl) the tissue wet weight (mg) and centrifuged at 16,000 x g for 20 min at 4°C, and the 
supernatant was removed. Tissue samples were assayed for DA by injecting a 20 μl aliquot of 
the sample onto a Reverse phase column (2.0 x 150 mm, ESA Inc., Chelmsford, MA). The 
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mobile phase consisted of 50 mM H2NaPO4, 0.72 mM sodium octyl sulfate, 0.075 mM 
Na2EDTA and 16% methanol (v/v), pH 2.7. The mobile phase was pumped through the system 
at 0.3 ml/min using a ESA 580 pump (ESA Inc., Chelmsford, MA). Analyses were performed 
using an ESA Coulochem Model 4100A detector, an ESA Model 5010 conditioning cell, and an 
ESA Model 5014B microdialysis cell (ESA, Inc., Chelmsford, MA). The settings for detection 
were E1=-75mV, E2=+220mV, and guard cell=+350mV. The limits of detection for DA were in 
the femtomole range. 
 
Statistical Analysis 
Data were analyzed with a two-way ANOVA, using Bonferonni-corrected multiple 
comparisons for post hoc analysis. There was no significant difference between the non-
immunoreactive area in striatum of animals treated with 6-OHDA at the 2 (n = 9), 4 (n = 8) and 8 
wk time points (n = 6), therefore these groups were pooled for further analysis. 
 
4.4 Results 
Distribution of exogenous GDNF after intrastriatal administration 
 No GDNF immunoreactivity was observed in animals treated with 6-OHDA alone 
or with the 6-OHDA vehicle (Fig 4.1) at any time point examined. Two weeks after infusion of 
GDNF a large spread of GDNF immunoreactivity beyond the cannula track was observed in the 
striatum of animals given GDNF, either alone or together with 6-OHDA. However, by 4 and 8 
wks, GDNF was largely confined to the cannula track. No GDNF was observed in the SN of any 
animals at any time points.  
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 Figure 4.1: Photomicrographs of GDNF-IR in the striatum. Sham animals (a) showed no 
GDNF-IR in the striatum, while GDNF-IR was present in the striatum of GDNF treated 
animals (2wks) (b), GDNF (4wks) (c), and GDNF (8wks) (d). 
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 Effect of GDNF on the 6-OHDA-induced loss of TH, DAT and VMAT2 immunoreactivity 
in the striatum  
 There was no significant difference in any of the three markers between animals 
treated with vehicle alone and GDNF alone. Animals treated with 6-OHDA alone displayed a 
significant increase in lesion area, measured by areas devoid of TH, DAT and VMAT2, as 
compared to vehicle treated (n = 7) and animals treated with GDNF alone (n = 10), who showed 
no loss of these markers at these same timepoints (p < 0.001; Fig 4.2,4.3,4.4) [Overall group 
effect: TH: (F(6,55) = 27.96; p < 0.0001; Fig 4.2); DAT: (F(6,55) = 22.29; p < 0.0001; Fig 4.3); 
VMAT2: (F(6,55) = 38.65; p < 0.0001; Fig 4.4) ]. At 2 wks, GDNF pre-treated animals (n = 10) 
did not show any appreciable protection against 6-OHDA toxicity when the TH, DAT, and 
VMAT2 markers were examined (Fig 4.2,4.3,4.4). At 4 wks, animals receiving GDNF prior to 
infusion of 6-OHDA (n = 9) showed a 70% reduction in lesion size with the TH and VMAT2 
markers (Fig 4.2, 4.4). Conversely, no significant reduction in lesion size was observed at 4 wks 
using the DAT marker. A significant reduction in lesion size was observed with TH, DAT and 
VMAT2 at 8 wks (n = 6) post-infusion showing an 84, 80, and 76% reduction, respectively, in 
the loss immunoreactivity (p < 0.001).  
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Figure 4.2: Effects of GDNF on TH+ terminals in the striatum after 6-OHDA. Loss of 
TH was prevented by GDNF prior to 6-OHDA infusion into the striatum at 4 and 8 but not 2wk 
post-6-OHDA. Vehicle and GDNF animals showed no significant loss of TH. 6-OHDA and 
GDNF+6-OHDA (2wk) animals displayed significant loss of TH when compared to vehicle 
treated animals (* p<0.01). This loss was attenuated in GDNF+6-OHDA (4wk) and GDNF+6-
OHDA (8wk) animals. All values are expressed as average lesion area in mm2 ± SEM.  
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Figure 4.3: Effects of GDNF on DAT+ terminals in the striatum after 6-OHDA. Loss of 
DAT was prevented by GDNF prior to 6-OHDA infusion into the striatum post-6-OHDA. Vehicle 
and GDNF animals showed no significant loss of TH. 6-OHDA animals displayed significant loss 
of TH when compared to vehicle treated animals (* p<0.01). This loss was attenuated in GDNF+6-
OHDA (2wk), GDNF+6-OHDA (4wk) and GDNF+6-OHDA (8wk) animals. All values are 
expressed as average lesion area in mm2 ± SEM. 
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Figure 4.4: Effects of GDNF on VMAT2+ terminals in the striatum after 6-OHDA. Loss of 
VMAT2 was prevented by GDNF prior to 6-OHDA infusion into the striatum at 4 and 8 but not 2wk 
post-6-OHDA. Vehicle and GDNF animals showed no significant loss of VMAT2. 6-OHDA and 
GDNF+6-OHDA (2wk) animals displayed significant loss of VMAT2 when compared to vehicle 
animals (* p<0.01). This loss was attenuated in GDNF+6-OHDA (4wk) and GDNF+6-OHDA (8wk) 
animals. All values are expressed as average lesion area in mm2 ± SEM. 
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Effect of GDNF on the 6-OHDA-induced loss of TH positive neurons  
  A significant loss of TH+ cells was observed at 2, 4, and 8 wks after 6-OHDA 
alone when compared to vehicle and GDNF treated animals (p<0.001) [Overall group effect: F (7, 
60) = 15.14; p < 0.001; Fig 4.5]. GDNF infusion prior to 6-OHDA did not prevent the loss of the 
TH phenotype at 2 wks. However, by 4 and 8 wks GDNF prevented the loss of the TH+ 
phenotype showing a significant difference from animals treated with 6-OHDA alone (p<0.001). 
A comparison of animals treated with vehicle alone and those treated with GDNF alone revealed 
no significant change in the number of TH+ cells (p>0.05).  
Effect of GDNF on the 6-OHDA-induced loss of Fluoro-gold positive neurons  
 6-OHDA-induced loss of TH+ cells in the SN could be a result of a loss of the TH 
phenotype rather than actual cell death or degeneration. Therefore, we examined the number of 
FG+ cells in the SN, as well as cells co-labeled with TH and FG. A significant 57% loss of FG+ 
cells was observed at 2 wks in animals given 6-OHDA alone (p<0.001). This loss of FG+ cells 
was even greater at 4 wks (78%; p<0.05) and 8 wks (83%; p<0.001). In contrast, GDNF prior to 
6-OHDA completely blocked loss of FG+ cells at each time point examined (p<0.001).  
 Co-labeling of cells with TH and FG was also examined. 6-OHDA produced a 
significant decrease of co-labeling of TH and FG at 2, 4, and 8 wks when compared to vehicle 
treated animals (p<0.001) [Overall group effect: Fluoro-gold: (F (7, 60) = 18.74; p < 0.001) Co-
label: (F (7, 60) = 41.81; p < 0.001) Fig 4.5]. Similarly, animals treated with GDNF prior to 6-
OHDA showed a significant decrease in co-labeling when examined at 2 wks and 4 wks post-6-
OHDA when compared to controls (p<0.001). Animals treated with GDNF prior to 6-OHDA 
observed at 8 wks post-6-OHDA showed no significant decrease in co-labeling and were 
significantly different from the groups receiving 6-OHDA only. 
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Figure 4.5a: Photomicrographs of TH+ cells in the SN. Sham animals (a), (b) and (c) showed no 
loss of TH+, FG+ or co-labeled cells, while 6-OHDA treated animals showed significant loss of 
TH+, FG+ and co-labeled cells at 8wks post-6-OHDA (e), (f) and (g) and arrow). (H) Animals 
administered GDNF prior to 6-OHDA showed a loss of TH+ cells at 2 wks post-6-OHDA but no 
significant loss at 4 and 8 wks post-6-OHDA (k) and (n). (I), (l) and (o) Animals administered 
GDNF prior to 6-OHDA showed no detectable loss of FG+ cells at 2, 4 and 8 wks post-6-OHDA. 
(J) and (m) Animals administered GDNF prior to 6-OHDA showed a loss of co-labeled cells at 2 
and 4 wks post-6-OHDA but no significant loss at 8 wks post-6-OHDA (p). 
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 Figure 4.5b: Effects of GDNF on loss of TH+ and FG+ cells in the SN after 6-OHDA. 
GDNF attenuated loss of TH+ cells in the SN at 4 and 8 but not 2wks post-6-OHDA. Vehicle 
and GDNF animals had no detectable loss of TH+ cells in the SN. 6-OHDA infusion 
significantly decreased the number of cells in the SN at 2, 4 and 8 wks post infusion in 6-
OHDA animals (*p < 0.001). Infusion of GDNF did not prevent a loss of TH+ cells in 
GDNF+6-OHDA (2wks) animals (*p<0.001) while no significant loss of TH+ cells was 
observed in GDNF+6-OHDA (4wks) and GDNF+6-OHDA (8wks). GDNF attenuated loss of 
FG+ cells in the SN at all timepoints post-6-OHDA. Vehicle and GDNF animals had no 
detectable loss of FG+ cells in the SN. 6-OHDA infusion significantly decreased the number of 
cells in the SN at 2, 4 and 8 wks post infusion in 6-OHDA animals (*p < 0.001). GDNF 
attenuated loss of cells co-labeled for TH and FG in the SN at 8 but not 2 or 4 wks post-6-
OHDA. Vehicle and GDNF animals had no detectable loss of co-labeled cells in the SN. 6-
OHDA infusion significantly decreased the number of cells in the SN at 2, 4 and 8 wks post 
infusion in 6-OHDA animals (*p < 0.001). Infusion of GDNF did not prevent a loss of co-
labeled cells in GDNF+6-OHDA (2wks) and GDNF+6-OHDA (4wks) animals (*p < 0.001) 
while no significant loss of colabeled cells was observed in GDNF+6-OHDA (8wks). All values 
are expressed average number of cells ± S.E.M.  
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 Effect of GDNF on the 6-OHDA-induced loss of DA content in the striatum  
 We assessed the loss of DA content at 2 and 4 wks after 6-OHDA ± GDNF 
pretreatment. No loss of DA was observed in animals treated with either vehicle alone or GDNF 
alone. 6-OHDA infused into the striatum produced a significant 60% loss of DA content in the 
striatum at both 2 and 4 wks post-6-OHDA when compared to animals treated with vehicle and 
GDNF alone (p<0.01) [Overall group effect: (F(4,24) = 13.89; p < 0.0001; Fig 4.5]. However, 
GDNF completely blocked the loss of DA content in the striatum when examined at 2 and 4 wks 
post-6-OHDA (Fig 4.6).  
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Figure 4.6: Effects of GDNF on DA content in the striatum after 6-OHDA. Loss of DA content 
was prevented by GDNF prior to 6-OHDA infusion into the striatum at 2 and 4 wks post-6-OHDA. 
Vehicle and GDNF animals showed no significant loss of DA content in the striatum. 6-OHDA 
animals displayed a significant decrease in DA content when compared to sham animals (* p<0.01). 
This loss was prevented in GDNF+6-OHDA (2wks) and GDNF+6-OHDA (4wks) animals. All values 
are expressed as % loss of DA content compared to the contralateral side ± SEM.  
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 4.5 Discussion 
GDNF is a promising neuroprotective factor in the treatment of PD. Animal studies have 
generally shown it to be protective against 6-OHDA and MPTP both in vitro and in vivo in 
animal studies (see Introduction). Clinical studies have been more equivocal with some groups 
reporting improvements in symptoms and pathology (Gill et al., 2003; Patel et al., 2005; Slevin 
et al., 2006), whereas others have shown no clinical improvement (Nutt et al., 2003; Lang et al., 
2006) (see Sherer et al., 2006 for review of the issues). Despite this controversy, it seems likely 
that a full understanding of the neuroprotective effects of GDNF will be useful in the 
development of much needed therapies for PD. Indeed, a better understanding of the changes 
produced by GDNF on the DA system may shed light on the best paradigms and markers to use 
in quantifying the benefits treatment.  
 Our study confirms previous studies indicating that GDNF can protect DA neurons from 
6-OHDA in the adult rat. It further extends that finding to examine the impact of GDNF on the 
phenotypic expression of DA neurons. This is critical since it has been reported that both MPTP 
and 6-OHDA can result in a loss of the TH phenotype without loss of DA neurons (Jackson-
Lewis et al., 1995; Ara et al., 1998; Rosenblad et al., 2003), and that infusion of GDNF into the 
SN can block the loss of SN cells produced by intra-nigral 6-OHDA without affecting the loss of 
TH itself (Lu and Hagg, 1997). In order to distinguish actual cell death from loss of the TH 
phenotype in the SN, we infused FG into the striatum 7 d prior to infusion of 6-OHDA to 
retrogradely label SN neurons affected by 6-OHDA. After 6-OHDA, a significant loss of FG+ 
cells was observed within 2 wks, which progressed over the time period examined. This is 
consistent with previous evidence of the progressive nature of the cell loss after intra-striatal 6-
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OHDA (Sauer and Oertel, 1994). 6-OHDA also caused a loss of TH+ cells. However, unlike the 
case for FG, this was maximal at the earliest time studied. This may reflect the fact that the initial 
loss of TH immunoreactivity demonstrates the downregulation of TH gene expression rather than 
actual cell loss. When neurons co-labeled for TH and FG were examined, 6-OHDA produced a 
sharp drop in the number of neurons at 2 wks, indicating that at this time point a large number of 
neurons labeled by FG do not contain TH at this time point (or the levels are below levels 
detectable by the assay). These data suggest that after a neurotoxic insult, loss of TH in SN 
neurons precedes actual cell death. This is in agreement with previous studies showing that TH is 
downregulated prior to actual cell death in response to injury to the nigrostriatal system 
(Jackson-Lewis et al., 1995; Ara et al., 1998; Rosenblad et al., 2003). GDNF did not block the 
loss of TH+ phenotype or cells co-labeled for TH and FG 2 wks after infusion of 6-OHDA but 
the system was able to normalize by 8 wks post-infusion, whereas no decrease in the number of 
FG+ neurons in animals treated with GDNF prior to 6-OHDA was observed between over 8 wks. 
These data suggest that whereas GDNF does not protect from an initial decrease in TH+ 
expression within SN after 6-OHDA, the system is able to normalize by 8 wks post-infusion and 
that no loss of overall cell number occurs when 6-OHDA is preceded by GDNF.  
A similar effect was observed in the striatum using immunohistochemistry to examine 
three phenotypic markers of DA terminal integrity, TH, DAT, and VMAT2. In animals exposed 
to GDNF and 6-OHDA there was a significant loss of all three markers 2 wks post-6-OHDA that 
had begun to recover at 4 wks and had further increased by 8 wks. The profiles and magnitude of 
the three markers differed to some extent. For example, 2 wks after animals received the 
combination of GDNF and 6-OHDA, the largest loss was with TH (20% of control); the loss of 
VMAT2 was smaller (35%), and the loss of DAT was smaller still (40%). This may suggest that 
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VMAT2 and DAT are less susceptible to stress-induced changes in the DA system. Indeed, 
others have suggested that VMAT2 is an optimal marker for DA terminal integrity because it is 
less susceptible to stress induced changes than other DA markers (Miller et al., 1999). 
Additionally, it is possible that because these proteins are rather different in location and 
function that the rates of turnover and synthesis of TH, DAT, and VMAT2 differ enough to 
account for the differences observed across this time course.  These data are in agreement with 
the data presented above from the SN, suggesting that like TH in the SN, phenotypic markers of 
DA terminal integrity are affected by 6-OHDA even in the presence of GDNF but that these 
phenotypes are able to normalize at later time points following 6-OHDA.  
GDNF itself has been shown to downregulate TH in the striatum and SN when 
overexpressed for an extended period of time in the striatum (Rosenblad et al., 2003). However, 
we feel that the possibility that GDNF alone is decreasing TH in these experiments is highly 
unlikely. First, in our study animals injected with GDNF alone showed no alterations in total TH 
protein at any of the 3 time points examined. Second, in the Rosenblad et al. (2003) study the 
GDNF gene was overexpressed using a viral vector producing levels of GDNF for much longer 
periods in the striatum than in the experiments discussed here.   
The inability of GDNF to protect from the initial 6-OHDA-induced decreases in markers 
of the DA system, raises the possibility that that the downregulation of these markers reflects a 
shift in the DA system from normal maintenance to a survival mode where the system has 
prioritized repair or regenerative responses over the synthesis and packaging of DA. Indeed, 
others have shown changes in both the activity and amounts of TH following damage to the 
nigrostriatal system (Reis et al., 1975). These data would support the hypothesis that GDNF does 
not prevent 6-OHDA from affecting the DA system but it allows the system to recover from the 
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initial insult in a manner that would not occur without GDNF pretreatment. Future experiments 
will explore functional changes in the DA system, measure DA release and neuronal activity 
after GDNF pretreatment and 6-OHDA.  
In order to determine the functional effects of GDNF following 6-OHDA, we examined 
DA content in a separate group of animals in the striatum at 2 and 4 wks post-infusion. 6-OHDA 
produced a significant loss of the neurotransmitter by 2 wks that persisted out to 4 wks following 
infusion of the toxin, while GDNF attenuated this loss at both time points. These data would 
suggest that although TH is decreased at 2 wks post-6-OHDA infusion in GDNF pretreated 
animals, GDNF allows the DA system to compensate and still function in a relatively normal 
manner. A likely explanation for this phenomenon is that because GDNF functions to enhance 
TH enzyme activity, normal levels of DA could be produced in the absence of normal levels of 
TH protein (Kirik et al., 2000; Lindgren et al., in preparation). Another possibility is that because 
GDNF has been shown to transiently increase tissue DA for 1-3 weeks in the striatum this may 
account for normal DA levels in the absence of the TH phenotype (Hudson et al., 1995; Beck et 
al., 1996; Martin et al., 1996, Rosenblad et al., 2003).  
 It had not previously been established whether GDNF remains present after 
infusion and if so for how long. We therefore used immunohistochemisty for the GDNF protein 
to determine how long GDNF remains present after our single infusion paradigm. In both 
animals treated with GDNF and 6-OHDA and animals treated with GDNF alone, GDNF was 
detectable at 2, 4, and 8 wks following infusion. The largest increase in GDNF staining was 
observed at 2 wks post-infusion, with staining at 4 and 8 wks largely confined to the cannula 
track. Although it is possible that the GDNF we detected includes endogenous GDNF increased 
in response to injury due to damage caused by 6-OHDA (Smith et al., 2003), this is unlikely 
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because animals treated with vehicle alone and 6-OHDA alone showed no immunoreactivity 
even along the cannula track.  
 It is unknown if the GDNF detected by immunohistochemistry at 2-8 weeks was 
biologically active. However, it is possible that the protein does continue to exert a physiological 
impact and thus plays a role in the dynamic changes in TH, DAT, and VMAT2 occurring over 
this time period. Another possibility is that the levels of GDNF detected between 2 and 8 wks are 
not functional, but that the GDNF quickly stimulates pro-survival intracellular signaling cascades 
whose end result is to protect DA neurons from cell death. These data would suggest that GDNF 
might provide long lasting effects on the nigrostriatal system long after the toxin is no longer 
present.  
Lu and Hagg (1997) have demonstrated the downregulation of TH after GDNF and 6-
OHDA and a neuroprotection of DA cell bodies measured by a retrograde tracer. Additionally, 
they reported that the recovery they observed disappeared if GDNF infusion was terminated. 
Although these data do not agree with the findings reported here there were several key 
differences in the experimental protocol in the two studies. First, in the previous report 6-OHDA 
was infused into the medial forebrain bundle, producing a much larger, more rapid loss of 
nigrostriatal DA neurons than in our striatal infusion model. Finally, while Lu and Hagg (1997) 
infused chronic GDNF into the SN, in our studies a single bolus of GDNF was infused in the 
striatum. This may be a crucial differences as it has been suggested that GDNF infused in the SN 
is ineffective at protecting axons and axon terminals from 6-OHDA (Kirik et al., 2004).  
Our current hypothesis is that GDNF protects from the loss of SN neurons and striatal 
terminals without preventing an early downregulation of TH, DAT, and VMAT2. However, it 
remains possible that whereas GDNF protects SN neurons, it does not protect terminals from 
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degeneration and that recovery of striatal terminals at later time points is a result of sprouting. 
GDNF has been shown to produce axonal sprouting in the striatum after a 6-OHDA infusion 
(Rosenblad et al., 1998; Rosenblad et al., 1999). Additionally, it has been hypothesized that 
axonal sprouting may be the one of the principal processes responsible for recovery of function 
when GDNF is administered following damage to the nigrostriatal system (Beck et al., 1995; 
Tomac et al., 1995; Rosenblad et al., 1998; 1999; Grondin et al., 2002). However, this possibility 
seems unlikely for several reasons. First, unlike other studies where GDNF induced sprouting 
was observed, in our studies GDNF was administered prior to 6-OHDA infusion. Second, we 
observed no change in tissue DA levels in animals treated with GDNF just prior to 6-OHDA, 
indicating some function of DA terminals. Finally, preliminary studies examining the role of 
GAP43, a marker of sprouting, indicate no increase in this protein following GDNF or GDNF 
and 6-OHDA administration.  
In conclusion, these data indicate that GDNF protects against the 6-OHDA induced loss 
of SN cells and DA transmitter levels but does not protect from the early decrease in phenotypic 
markers of the DA system. This would also suggest that the protective effects of GDNF from 6-
OHDA are time dependent and that the loss of phenotypic markers in this system does not 
inevitably lead to cell death. They also suggest that human studies of GDNF-induced protection 
must be carefully timed in both the administration of the protein and measurement of its efficacy, 
in order to avoid the pitfalls of falsely interpreting temporary loss of phenotype. Because GDNF 
regulates TH directly (Kobori et al. 2004; Salvatore et al. 2004) it is possible that interpretation 
of the protective effect of GDNF on DA neurons using only the TH marker could be confounded. 
Further exploration of the neuroprotective effects of GDNF on a 6-OHDA model will provide 
insight into design and methodology of future clinical studies on the effects of GDNF and PD. 
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Additionally as the mechanisms of the protective effects of GDNF are further explored more 
targets for drug creation may become available, particularly as early detection methods become 
more readily available.  
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 5.0 Discussion 
 
Current treatments for PD, such as L-dopa, only alleviate the symptoms of the disease 
and can lose their efficacy and produce side effects over time (Pahwa and Lyons, 2004). Thus, it 
is important that new therapeutic approaches that slow or block the neurodegenerative process 
be explored. One such approach is exercise. Exercise has been known for some time to have 
beneficial effects on the brain (for review see Mattson, 2000). Indeed, exercise has been shown 
to protect from brain damage, in animal models of ischemia, (e.g. Stummer et al., 1994, Li et 
al., 2004), 3-acetylpyrine, domoic acid, (Carro et al. 2001), animal models of Alzheimer’s 
disease (Allard et al., 2005; Jankowsky et al., 2005; Sisodia et al., 2005). Similarly, in animal 
models of PD, running, either forced or voluntary, as well as an enriched environment, has been 
shown to reduce the effects of PD models (Bezard et al., 2003; Tillerson et al., 2003; Faherty et 
al., 2005). 
Whereas the mechanism by which exercise confers its protective effects is unknown, it is 
well established that exercise confers changes in the brain that produce an environment 
conducive to cell survival. For example, as I have discussed in the Introduction, exercise 
produces increases in synaptogenesis, neurogenesis, and growth of neuronal processes. Here I 
have chosen to focus on exercise-induced increases in trophic factors. Exercise increases several 
trophic factors, including BDNF and GDNF (e.g. Neeper et al., 1995; 1996; Young et al., 1999), 
both of which promotes the survival of DA neurons and that are promising neuroprotective 
factors in the treatment of PD.  
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Based on this body of literature, in this dissertation I chose to focus on neuroprotective 
roles of exercise and GDNF on the effects of 6-OHDA in an animal model of PD. In this 
Chapter, I will first briefly summarize my results (Section 5.1). This will be followed by a 
discussion of some of the key issues raised by these results (Sections 5.2-5). Next, I will discuss 
the clinical significance of my results. I will end with a brief discussion of what I consider the 
most important future directions (Section 5.7) to be taken and the overall conclusions that I feel 
can be drawn from this work (Section 5.8). 
 
5.1 Summary of Results  
5.1.1 Forced limb use protects from 6-OHDA induced behavioral deficits, loss of 
striatal DA, and loss of TH+ neurons and terminals.  
 In the Chapter 2, my colleagues and I report that forced limb use for the 7 days prior to 6-
OHDA infusion along the MFB produced a robust attenuation of the behavioral and 
neurochemical effects of the 6-OHDA lesion model. Behaviorally, animals infused with 6-
OHDA showed profound deficits in the use of the forelimb corresponding to the infused 
hemisphere and displayed both forelimb akinesia and robust rotation in response to 
apomorphine. In contrast, animals casted for the 7 days prior to 6-OHDA displayed no 
behavioral deficits in response to the toxin, such that they were statistically indistinguishable 
from controls. The ability of casting to protect against the behavioral effects of 6-OHDA is a 
likely result of the casting-induced attenuation of the loss of DA. The neuroprotective effects 
conferred by prior forced limb use on behavior and DA levels after 6-OHDA were striking, but 
several factors remained unknown. First, as discussed in section 5.2, it was not clear whether the 
forced limb use produced an overuse of the non-casted forelimb and thus could be referred to as 
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a form of exercise or over-use. Second, there were several possible explanations for the ability of 
forced motor activity to reduce the behavioral and neurochemical effects of 6-OHDA. For 
example, animals could be learning a different strategy for executing the behavioral tasks being 
tested, DA release from remaining DA terminals could increase, damaged axons could 
regenerate, intact neurons could sprout, or neurogenesis might occur. These are each explored 
below. 
In Chapter 3, we used immunohistological analysis to determine the effect of prior forced 
limb use on TH+ terminals and cell bodies in the striatum and SN respectively after 6-OHDA 
toxicity. Additionally, to distinguish between actual cell death and loss of the TH phenotype in 
the SN, we examined the SN for Nissl-positive neurons. Given the high proportion of DA 
neurons to total neurons within the SN, this provided an approximation of the number of DA 
neurons present that was independent of their expression of the TH+ phenotype. We observed 
that prior forced limb use prevents the loss of TH+ terminals in the striatum. 6-OHDA caused a 
significant loss of TH+ terminals in the striatum, whereas animals exposed to forced limb use 
followed by 6-OHDA showed no sign of loss of TH+ terminals in the striatum over a 28 day 
period. 6-OHDA treatment produced a significant loss of TH+ cells and of cells positive for Nissl 
substance indicating that 6-OHDA produces cell death in the SN rather than only a loss of the 
TH phenotype in these neurons. However, forced limb use blocked both the loss of TH+ cells and 
cells positive for Nissl substance at 7 and 28 days after infusion of 6-OHDA, supporting the 
hypothesis that forced limb use for the 7 days prior to 6-OHDA infusion prevents degeneration 
in the nigrostriatal DA system. The neuroprotective effects of forced limb use on TH in the 
nigrostriatal system and cell survival in the SN are consistent with the observations made in 
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Chapter 2 demonstrating the neuroprotective effects of prior forced limb use on DA levels in the 
striatum and behavior.    
 
5.1.2 Forced limb use produces an increase in GDNF in the striatum  
Our working hypothesis was that the casting-induced attenuation of the loss of striatal 
DA was, in turn, a result of an exercise-induced increase in GDNF in the region that 
subsequently received 6-OHDA. In order to examine the role GDNF plays is casting-induced 
neuroprotection we examined levels of GDNF during the casting period in Chapter 2. GDNF was 
increased significantly in the striatum at 1 and 3 day following placement of the cast but had 
returned to baseline levels by day 7. Although GDNF had declined to baseline prior to 6-OHDA 
infusion, this does not preclude GDNF as a possible participant in the neuroprotective effects of 
forced limb-use. Indeed, previous investigators have shown that exogenous GDNF can be 
neuroprotective if administered as much as 7 days prior to 6-OHDA (Kearns & Gash, 1995; 
Choi-Lundberg et al., 1998). This may mean that GDNF triggers longer lasting secondary 
intracellular responses such as the activation of specific intracellular cascades (see section 5.7.5). 
 
5.1.3 GDNF protects SN neurons from 6-OHDA induced toxicity but does not 
immediately prevent from loss of the TH phenotype 
In the previous chapters of this dissertation, I have explored the neuroprotective effects of 
prior forced limb use on the effects of 6-OHDA in a rat model. I have shown that forced limb use 
for the 7 d prior to 6-OHDA infusion produces a robust neuroprotective effect on the behavioral 
deficits, loss of DA and loss of TH+ terminals and cell bodies. Additionally, I have shown that a 
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rise in GDNF is correlated with the protective effects of forced limb use. However, it will be 
necessary to perform additional studies to more stringently test the hypothesis that changes in 
GDNF expression are actually causally related to the changes in behavior and/or DA levels. 
One would like to examine the neuroprotective effects of forced limb use in animals in 
which endogenous GDNF is blocked. This could be achieved using several approaches 
including, blocking antibodies, antisense RNA to block production of the protein, or use 
transgenic animals. Whereas these approaches may be the most direct test of the hypothesis that 
GDNF is responsible for the neuroprotective effects of 6-OHDA, it faces several drawbacks. 
Although some investigators have succeeded in studying the role of GDNF with blocking 
antibodies (Oo et al., 2003), in vivo antisense technology generally has not been capable of 
completely blocking synthesis of the protein (see Batchelor et al., 2000). Additionally, both 
blocking antibodies and antisense probes for GDNF may cause an alternate pathway (see below) 
to increase. Thus, it may be necessary to block multiple trophic factors at one time in order to 
establish a role for trophic factors in the protective effects of forced limb use. Although 
knockout animals generally can avoid the pitfalls discussed above, mice homozygotic for 
GFRα1, the GDNF receptor, expire soon after birth (Rossi et al., 1999). In summary, in the 
experimental paradigms discussed above interpretation of negative data poses a major challenge, 
presenting several possibilities including that the trophic factor in question is truly not involved, 
the blocking technique utilized did not work, or that an alternate pathway is compensating for the 
decrease in trophic factor signaling.  
Given these technical and interpretational problems, I chose an alternate approach to 
establish a neuroprotective role for GDNF, direct infusion of the exogenous protein. Although 
this approach does not directly mimic the GDNF induced increase in forced limb use, I believed 
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it would provide insight into the neuroprotective effects observed in Chapters 2 and 3 without the 
technical burden of the techniques discussed above.  
To elucidate further the role GDNF may play in neuroprotection, in Chapter 4 we 
examined the time course of these effects. Most studies to date have examined the effects of 
GDNF on 6-OHDA after an extended period, but there is very little evidence on the effects of 
GDNF on multiple phenotypic markers during the progression of cell death that typically occurs 
after 6-OHDA infusion in the striatum. Thus, in Chapter 4, we examined the role of GDNF after 
6-OHDA infusion over an 8-wk period, using three phenotypic marker of the DA system, TH, 
DAT, and VMAT; a non-phenotypic marker in FG; and tissue DA levels.  
After administration of 6-OHDA, a significant loss of TH+ cells was observed by 2 wks 
post-infusion and persisted at 4 and 8 wks. 6-OHDA caused a loss of cells positive for FG as 
well a progressive loss at each time point examined demonstrating the progressive nature of the 
striatal lesion model (Sauer and Oertel, 1994). Additionally, where neurons co-labeled for TH 
and FG were examined, 6-OHDA produced a sharp drop in the number of neurons at 2 wks, 
indicating that a large number of neurons sending projections to the striatum from the SN do not 
contain TH or the levels are below our limits of detection. These data indicate that after a 
neurotoxic insult, loss of TH in SN neurons precedes actual cell death.  
GDNF did not block the loss of TH+ phenotype or cells co-labeled for TH and FG 2 wks 
after infusion of 6-OHDA. However, the number of TH+ and co-labeled neurons began to 
increase by 4 wks and had returned to baseline by 8 wks after infusion of GDNF and 6-OHDA. 
Conversely, when the number of FG+ neurons was examined in animals treated with GDNF prior 
to 6-OHDA, no appreciable difference was observed in comparison to control animals at 2, 4, or 
8 wks. These data suggest that whereas GDNF does not protect from an initial decrease in TH+ 
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cells after 6-OHDA, the system is able to rebound its ability to produce TH by 8 wks post-
infusion, and that no loss of overall cell number occurs as a result of 6-OHDA infusion. This 
could suggest that the downregulation of TH reflects a shift in the DA system from normal 
maintenance to a survival mode where the system has prioritized repair or regenerative responses 
over the synthesis and packaging of DA (Reis et al., 1975). 
 
5.1.4 GDNF-induced protection from the loss of TH, DAT, or VMAT 
immunoreactive terminals in the striatum is delayed by several weeks 
In Chapter 4, DA terminals in the striatum were examined for several phenotypic markers 
of DA neurons, TH, DAT and VMAT immunoreactivity following GDNF and 6-OHDA 
infusions. Similar to the effects observed in the SN, 6-OHDA produced a loss of all three 
markers at 2 wks that persisted to 8 wks. In animals exposed to both GDNF and 6-OHDA there 
was still a significant loss of all three phenotypes at 2 wks post-6-OHDA. However, this had 
begun to recover at 4 wks and had further increased by 8 wks. The profiles and magnitude of the 
three markers differed slightly. The largest loss at 2 wks after GDNF and 6-OHDA was with TH, 
followed by a smaller loss of VMAT2 and an even smaller loss of DAT.  This may suggest that 
VMAT2 and DAT are less susceptible to stress-induced changes in the DA system. Indeed, 
others have suggested that VMAT2 is an optimal marker for DA terminal integrity due its 
stability (Miller et al., 1999).   
These data provide further support the hypothesis that the phenotypic markers of DA 
terminal integrity are affected by 6-OHDA even in the presence of GDNF, but that these 
phenotypes are able to normalize by 8 wks following 6-OHDA. These data also highlight the 
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importance of using multiple markers of terminal and neuronal integrity when examining cell 
death. 
 
5.1.5 GDNF prevents loss of tissue DA following 6-OHDA 
Whereas we have established that GDNF protects from loss of nigral neurons, it was not 
clear if the changes in TH, DAT, or VMAT2 had an impact on DA content in the striatum. 6-
OHDA produced a significant loss of the neurotransmitter by 2 wks that persisted out to 4 wks 
following infusion of the toxin, while GDNF attenuated this loss at both time points. These data 
would suggest that although TH is decreased at 2 wks post-6-OHDA infusion in GDNF 
pretreated animals, GDNF allows the DA system to compensate and still function in a relatively 
normal manner. The ability of DA to remain normal in the absence of TH may be related to the 
ability of GDNF to regulate the activity of the TH enzyme, thereby increasing the activity of the 
remaining TH to a degree where DA synthesis appears normal (Kirik et al., 2000; Lindgren et al., 
in preparation).  
 
5.2 Forced limb use produces “overuse” of the non-casted forelimb 
The protective effects of forced limb use were established in Chapters 2 and 3, but it 
remained unknown if the effects of forced-limb use can be attributed to “overuse” of the non-
casted forelimb. Tillerson and colleagues (2002) have suggested that use of the impaired limb 
following the removal of the cast is imperative for maintenance of the behavioral effects observed in 
a model using forced limb use following 6-OHDA infusion. They demonstrate that if, after casting 
the unimpaired forelimb on days 1-7, and subsequently casted the impaired forelimb for days 7-14, 
the behavioral sparing that had been evident following forced use was lost and remained 
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compromised for at least 40 days post-6-OHDA. These data indicate the importance of continued use 
of the affected limb (Tillerson et al., 2002). In order to determine if casted a forelimb increases the 
use of the non-casted forelimb in the model of prior forced limb use, in Chapter 3 we observed 
casted and non-casted animals in their home cage during the casting period. Two days after 
placement of the cast, casted animals used their forelimb significantly less than non-casted 
animals. However, this effect was attenuated by 3 days post-cast. Indeed, not only did casted 
animals begin to use their non-casted limb as much as the corresponding limb of non-casted 
animals but they began to use the non-casted limb as much as non-casted animals used both 
forelimbs. These data indicate that the protective effects of forced limb use could function 
through an increase in use of the non-casted forelimb.  
 
5.3 Mechanism of exercise induced GDNF 
It is not known how exercise functions to increase trophic factor expression although 
several possibilities exist. The first possibility is that forced limb use functions to increase motor 
learning, forced use requires the animals to engage in alternative strategies for eating, drinking, 
and ambulating in their cages.  These adaptive responses would likely produce motor learning 
responses in the brain that are well known to induce trophic factor expression (Gomez-Pinnila et 
al., 1998; Kliem et al., 2003). Exercise has been shown to increase glial cell proliferation 
(Gomez-Pinnila et al., 1998; Holmes et al., 2004; Li et al., 2005) and the role of glial cells 
providing trophic support for neurons is well established (Darlington, 2005). Therefore, it is 
possible that a forced limb use-induced increase in glia could function to increase GDNF.  
Because the RET and GFR-ά are located on DA neurons, another cell type could likely function 
to release GDNF (Treanor et al., 1996; Smith et al., 2003). Additionally, it has been shown that 
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GDNF mRNA is expressed in the adult brain in several regions receiving projections from the 
nigra, including striatum, nucleus accumbens, thalamic nuclei, olfactory tubercle, hippocampus, 
cerebellum, cingulate cortex and olfactory bulb (Trupp et al., 1997). It will be important in future 
experiments to localize the increase in GDNF to particular cell type to further examine this 
hypothesis. Finally, as discussed in detail below it is possible that stress may play a large role in 
the exercise induced increase of GDNF.  
 
5.4 Differences in exercise induced and GDNF induced neuroprotection 
Important differences in the types of neuroprotective effects of GDNF and exercise were 
observed in these studies. First, forced limb use prior to 6-OHDA confers a more complete 
neuroprotection with no downregulation of TH, whereas, exogenous GDNF pretreatment does 
not protect from the initial decrease in TH. Although this difference may indicate that GDNF is 
not involved in the protective effects of exercise, as discussed below, I believe that it is more 
likely that it reflects one or more of several differences between the use of exercise and 
exogenous GDNF as neuroprotective treatments. First, in our study the exercise occurred over a 
period of 7 days prior to the administration of 6-OHDA (Chapter 2 and 3), whereas exogenous 
GDNF was given in a single bolus 6 hours before 6-OHDA (Chapter 4). Second, the amount and 
location of the increased endogenous GDNF that developed after exercise was undoubtedly 
different from that for exogenous GDNF. Third, it is highly likely that exercise produced many 
changes in addition to the rise in GDNF that we reported. My conclusion is that that exercise is 
likely to be a more potent protective approach than administration of GDNF alone.  
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5.5 GDNF remains present in the striatum up to 8 weeks following infusion  
It is not well established how long GDNF remains present following infusion but as 
discussed above, it has been shown that GDNF can confer neuroprotection when administered 
long before infusion of a neurotoxin. Establishing the temporal kinetics of GDNF remained an 
important issue, as it was unknown how long exogenous GDNF could confer protective effects 
on a compromised nigrostriatal pathway. Other groups have shown that removal of the GDNF 
stimulus reverses the protective benefits of the protein (Lu and Hagg, 1997). We therefore 
examined the presence of GDNF in the striatum at 2, 4, and 8 wks following infusion. In both 
animals treated with GDNF, the protein was detectable at 2, 4, and 8 wks following infusion. The 
largest increase in GDNF staining was observed at 2 wks post-infusion, with staining at 4 and 8 
wks largely confined to the cannula track. I assume that this GDNF staining is due to the actual 
infusion of GDNF rather than a generic reaction to injury as animals treated with vehicle alone 
and 6-OHDA alone showed no GDNF immunoreactivity even along the cannula track. These 
data suggest that the effects of a single bolus of GDNF can be long lasting conferring beneficial 
effects long after infusion of the protein.  
Although these data are not in agreement with previous findings, it is likely that 
differences in location of the infusion of GDNF could result in differences in the kinetics of the 
protein. Lu and Hagg (1997) infused chronic GDNF into the SN, whereas in our studies a single 
bolus of GDNF was infused in the striatum. This may be a crucial differences as it has been 
suggested that GDNF infused in the SN is ineffective at protecting axons and axon terminals 
from 6-OHDA (Kirik et al., 2004).  
 
5.6 Clinical applications of exercise and GDNF 
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The data presented in this dissertation suggest the both exercise therapy and GDNF 
infusion are able to prevent the neurotoxic effects of oxidative stress and thus are treatment 
alternatives for PD. Whereas forced-limb use has been shown produce beneficial effects 
clinically in other conditions (Taub et al., 1999; Liepert et al., 2000; Taub and Morris, 2001), it 
may not be an ideal physical therapy regime for PD patients. Although PD commonly presents 
itself unilaterally, it typically progresses to a bilateral disorder, making forced use of a single 
forelimb not ideal. However, others have focused on bilateral forms of exercise in experimental 
animals and in patients, supporting the hypothesis that exercise regimens can be used as a 
therapy (see Introduction).  
Despite the likely efficacy of bilateral forms of exercise in PD, additional issues remain. 
As the disease progresses, movement becomes more difficult and therefore exercise regimes for 
later-stage patients will have to be tailored to the motor progression of PD and compliance to an 
exercise program may prove to be more difficult. Third, most of the exercise regimes that have 
been used in experimental animals (e.g., treadmill, running wheels, balance beams) are not 
readily available to many individuals. 
One plausible clinical alternative to the use of exercise in the treatment of PD would be to 
take advantage of the molecules that appear to be endogenously increased by exercise. One such 
example is GDNF. Infusion of GDNF into patients with PD has been explored by several groups 
but the data remain quite controversial, as some groups have reported improvements in 
symptoms and pathology (Gill et al., 2003; Patel et al., 2005; Slevin et al., 2006) while others 
have shown no clinical improvement (Nutt et al., 2003; Lang et al., 2006). For GDNF or GDNF 
agonists to become an effective treatment option for PD, it will be necessary to standardize 
methods for delivery and the markers used for reporting improvements, particularly in the 
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pathology of the disease. As indicated in Chapter 4, it may be crucial to develop markers not 
reliant on phenotypes in the DA system, as they seen to change in response to stress, as this may 
lead to falsely discarding treatment options that may in fact be effective over time. A challenge 
to the clinical use of GDNF has been the inability of the molecule to cross the blood brain barrier 
requiring intracranial delivery of the protein, if a small molecule that mimicked the actions of 
GDNF would be ideal for the treatment of PD (eg Lin et al., 2004). Another related approach 
might be to develop drugs that act intracellulary to trigger processes that normally are stimulated 
by GDNF, such as the activation of ERK or Akt (see below). However, by bypassing the 
receptor for GDNF, one runs the risk of increasing the non-specific effects of such treatments. 
 
5.7 Future directions 
5.7.1 Analysis of other trophic factors  
In this dissertation, I have chosen to focus on GDNF but there are many other trophic 
factors that may play a role in casting-induced neuroprotection. Exercise has been shown to 
increase BDNF and NGF (Neeper et al., 1996), FGF-2 (Gomez-Pinilla et al., 1995), and IGF-1 
(Carro et al., 2001) in the CNS. Each of these factors could be a likely candidate for protection of 
the DA system, as these factors have been shown to have potent trophic activity towards DA 
neurons (Hyman et al, 1991; Altar et al., 1992; Lin et al., 1993; Winkler et al., 1996) and, where 
examined, has been shown to protect against the neurotoxic effects of 6-OHDA (Hoffer et al., 
1994; Kearns & Gash, 1995; Levivier et al., 1995; Choi-Lundberg et al., 1998; Akerud et al., 
1999; Gong et al., 1999; Kramer et al., 1999; Schatz et al., 1999; Shults et al., 2000; Wang et al., 
2002)..  Examining each of these factors will be crucial in establishing the mechanism for 
exercise-induced neuroprotection as it seems likely that more than one factor will ultimately be 
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found to be responsible for exercise-induced protection. To this end, FGF-2, one of the trophic 
factors shown to be upregulated by exercise (Gomez-Pinilla et al, 1995), has also been shown in 
vitro to induce expression of both GDNF and BDNF (Suter-Crazzolara and Unsicker, 1996; 
Kwon, 1997). 
5.7.2 Analysis of the role of stress in the neuroprotective effects of exercise 
Although our focus has been on trophic factors as the mechanism for forced-limb use 
induced neuroprotection, there are other factors that may play a role. One such factor is stress, 
although forced limb use has positive effects on the brain, it also can be regarded as a form of 
restraint stress and thus, would be expected to stimulate the hypothalamic-pituitary-adrenal 
(HPA) axis. Whereas stress is normally classified as a neurotoxic factor, stress has also been 
shown to have neuroprotective effects (Sloviter et al., 1989; Chadi et al., 1993; Follesa and 
Mocchetti, 1993; Mocchetti et al., 1996; Sousa et al., 1999). It is possible, therefore, that the 
HPA axis plays a pivotal role in forced limb use protection through stimulated neurotrophic 
factor expression or through the production of melanocortins, both of which have been shown to 
have neuroprotective effects in various peripheral and central nervous system injury models 
(Sloviter et al., 1989; Chadi et al., 1993; Follesa and Mocchetti, 1993; Mocchetti et al., 1996; 
Sousa et al., 1999). It is possible that the increases in GDNF observed following forced limb use 
are a result of HPA axis induced increases in trophic factors, as discussed above, rather than as a 
result of an increase in limb use.  
5.7.3 Analysis of other exercise regimes 
As noted above, forced limb use may not be the ideal form of exercise to use in the 
clinical setting, it is therefore important to examine other forms of exercise in animal models of 
PD to determine if another form of exercise could be more efficacious and more clinically 
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applicable. Indeed, others have examined treadmill and exercise in a running wheel, as well as an 
enriched environment and have shown neuroprotective effects in an MPTP in a mouse model of 
PD (Bezard et al., 2003; Tillerson et al., 2003; Faherty et al., 2005). It is important to note that in 
some studies where the effects of exercise have been examined complete protection has not been 
observed, Poulton and Muir (2005) observed behavioral protection from 6-OHDA but failed to 
demonstrate protection of DA neurons in animals who ran prior to 6-OHDA. These data raise the 
possibility that different types and durations of exercise may produce different results, 
demonstrating the necessity of further exploration of these differences.  
5.7.4 Role of exercise in non-motor effects of PD 
As discussed in Chapter 1, PD is not only manifested as a motor disorder but also 
produces non-motor symptoms, including depression, cognitive deficits, autonomic dysfunction 
and anosmia. To date, the focus on the protective effects of exercise has been on the motor 
symptoms and systems associated with an animal model of PD. I believe this will be an 
important effect to explore as others have shown that exercise and neurotrophic factors both 
decrease depressive symptoms and cognitive deficits in animal models (for reviews see: Mattson 
et al., 2001; Duman et al., 2005). Indeed, our laboratory has preliminary results indicating that 
forced limb use protects from 6-OHDA induced damage to the nucleus accumbens and the 
ventral tegmental area.  
5.7.5 The mechanism of trophic factor induced neuroprotection 
I believe that trophic factors play a major role in the protective effects of forced limb use, 
but it remains unknown how specifically they confer these effects. GDNF appears to act via a 
plasma membrane receptor complex consisting of GFRα1 and RET, which in turn triggers 
several signaling cascades (for review see: Airaksinen et al., 1999). Two possible signaling 
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cascades that have been shown to be activated by GDNF are the phosphatidylinositol 3-kinase 
(PI 3K)/Akt and the Ras/extracellular signal-regulated kinase (ERK) signaling pathways. It is 
known that GDNF activates ERK (Soler et al., 1999; Trupp et al., 1999) and that blockade of the 
ERK pathway attenuates GDNF-induced survival in cultures of hippocampal neurons and cilliary 
ganglion neurons (e.g., Lenhard et al., 2002; Peterziel et al., 2002; but see also Soler et al., 
1999). In addition, to the ERK pathway, some of the effects of GDNF may be mediated by Akt. 
GDNF has been shown to activate Akt (van Weering & Bos, 1998; Soler et al., 1999; Besset et 
al., 2000; Jin et al., 2002; Neff et al., 2002; Perez-Garcia et al., 2004) and that blockade of this 
pathway blocks GDNF induced survival (Soler et al., 1999). Data from our lab also indicate that 
the protective effects of GDNF against 6-OHDA may be mediated in part by activation of Erk1/2 
and Akt in a DA-like cell line (Ugarte et al., 2003). Additionally, preliminary data from our lab 
indicate that in vivo exercise and GDNF increase Erk 1/2 and that GDNF increases Akt in the 
striatum and SN. These data suggest that further exploration of the time course of activation of 
these factors is merited, particularly in light of the fact that a causal relationship can be easily 
established because pharmacological inhibitors for both the ERK and Akt pathways exist. In 
addition, further analysis of these pathways may provide more targets for drug creation, 
particularly as early detection methods become more readily available.  
 
5.8 Conclusions 
The data presented in this dissertation provide a basis for the neuroprotective effect of 
exercise in an animal model of PD, with that effect involving an increase in GDNF. We 
demonstrated here that forced limb use substantially attenuates the behavioral, neurochemical, 
and neuroanatomical effects of 6-OHDA into the nigrostriatal pathway. Additionally, we showed 
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that forced limb use produces a robust increase of GDNF protein in the striatum, indicating a role 
for trophic factor signaling in the neuroprotective effects of forced limb use. Finally, to further 
explore the protective effects of GDNF, we observed that GDNF protects DA neurons from cell 
death after 6-OHDA but does not protect from the early loss of phenotypic markers of the DA 
system, but is able to normalize after 6-OHDA infusion. Taken together these data suggest that 
exercise and GDNF are viable potential treatment options for PD, but that care must be taken in 
the analysis of markers of the DA system when evaluating neuroprotection.  
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